Page last updated: 2024-11-07

cp-55,940

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID104895
CHEMBL ID_75020
CHEMBL ID48552
CHEMBL ID559612
SCHEMBL ID120410
MeSH IDM0154196

Synonyms (73)

Synonym
kfy70972j5 ,
unii-kfy70972j5
cp-55940
smr001230653
MLS002153159
cp-55940 [(-)-ac],xiv
5-(1,1-dimethyl-heptyl)-2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxy-propyl)-cyclohexyl]-phenol
chembl_75020
chembl48552
bdbm50072775
2-((1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol
5-(1,1-dimethyl-heptyl)-2-[(4r,6r)-5-hydroxy-2-((r)-3-hydroxy-propyl)-cyclohexyl]-phenol
gtpl730
gtpl734
PDSP2_000199
EU-0100189
cp-55940, >98% (hplc), powder
LOPAC0_000189
phenol, 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-, (1alpha,2beta,5alpha)-
cp-56,667
cp 56667
phenol, 5-(1,1-dimethylheptyl)-2-((1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-, rel-
5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)phenol
NCGC00015212-01
lopac-c-1112
PDSP2_000671
[3h]cp55940
cp 55,940
cp-55,940
cp55940
NCGC00024896-02
NCGC00024896-03
83003-12-7
(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-trans-4-(3-hydroxypropyl)cyclohexanol
cp55,940
C 1112
NCGC00024896-05
CHEMBL559612
2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-5-(2-methyloctan-2-yl)phenol
NCGC00024896-04
CCG-204284
HMS2236E04
8yx8jk1bqg ,
(+-)-cp 55940
unii-8yx8jk1bqg
LP00189
5-(1,1-dimethylheptyl)-2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]phenol
(-)-cp-55940
j259.891d ,
phenol, 5-(1,1-dimethylheptyl)-2-((1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-
SCHEMBL120410
YNZFFALZMRAPHQ-SYYKKAFVSA-N ,
rel-5-(1,1-dimethylheptyl)-2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol
AKOS024458710
HMS3649D17
SR-01000597481-1
sr-01000597481
SR-01000075740-1
sr-01000075740
DTXSID80875516
(1r,3r,4r)-3-[2-hydroxy-4-(1,1-dimethylheptyl)phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol
cp-55940, (+/-)-
phenol, 5-(1,1-dimethylheptyl)-2-(5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-, (1.alpha.,2.beta.,5.alpha.)-
(+/-)-cp-55940
SR-01000075740-4
(+/-)-cp 55,940
DTXSID401017713
9gf ,
phenol,5-(1,1-dimethylheptyl)-2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-, rel-(-)-
SDCCGSBI-0050177.P002
nsc-792743
nsc792743
phenol, 5-(1,1-dimethylheptyl)-2-[(1r,2r,5r)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Furthermore, compound 4-9 had good oral bioavailability (F=52%, 3mg/kg)."( N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
Iida, I; Ishizaka, T; Ohta, H; Saito, S; Tatsuzuki, M; Toda, Y; Tomishima, Y; Yoshinaga, M, 2007
)
0.34
" The oral bioavailability of these compounds could be dramatically improved by optimization studies of the side chains attached to the indole and oxadiazole cores, leading to identification of a CB1 receptor agonist with good oral activity in a range of preclinical models of antinociception and antihyperalgesia."( Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
Adam, JM; Baker, J; Campbell, R; Clark, JK; Cottney, JE; Davies, K; Deehan, M; Easson, AM; Edwards, D; Epemolu, O; Evans, L; Feilden, H; Fields, R; Francis, S; Jeremiah, F; Kiyoi, T; McArthur, D; Morrison, AJ; Prosser, A; Ratcliffe, PD; Schulz, J; Wishart, G, 2011
)
0.37
"Novel, low brain penetrant, orally bioavailable CB1 receptor agonists were designed starting from a mature lead series of potent brain penetrant CB1 receptor agonists."( Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
Adam, JM; Baker, J; Boyce, S; Campbell, R; Clark, JK; Cottney, JE; Davies, K; Deehan, M; Everett, K; Fields, R; Francis, S; Jeremiah, F; Kiyoi, T; Maidment, M; Martin, I; Morrison, A; Prosser, A; Ratcliffe, P; Schulz, J; Wishart, G, 2012
)
0.38
", ip) indicate that the liver is the primary site of biotransformation of the compound, suggesting that both 22a and its metabolite(s) are active, compensating probably low bioavailability of the parent molecule."( Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
Bednarski, M; Gunia-Krzyżak, A; Marona, H; Nitek, W; Pękala, E; Powroźnik, B; Słoczyńska, K; Walczak, M; Waszkielewicz, AM; Żesławska, E, 2016
)
0.43
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (68)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency35.48130.003245.467312,589.2998AID1705
Chain A, Beta-lactamaseEscherichia coli K-12Potency18.06350.044717.8581100.0000AID485294; AID485341
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency56.23410.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency14.12545.623417.292931.6228AID2323
Chain A, CruzipainTrypanosoma cruziPotency25.11890.002014.677939.8107AID1476
endonuclease IVEscherichia coliPotency31.62280.707912.432431.6228AID1708
thioredoxin reductaseRattus norvegicus (Norway rat)Potency36.01310.100020.879379.4328AID488772; AID588453; AID588456
ATAD5 protein, partialHomo sapiens (human)Potency24.83850.004110.890331.5287AID493106; AID493107; AID504466
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency21.61470.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency9.10640.00527.809829.0929AID588855
DNA polymerase III, partialBacillus subtilisPotency23.77811.062114.152826.6795AID485295
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency31.62280.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency6.30960.001318.074339.8107AID926; AID938
regulator of G-protein signaling 4Homo sapiens (human)Potency37.68580.531815.435837.6858AID504845
nonstructural protein 1Influenza A virus (A/WSN/1933(H1N1))Potency63.09570.28189.721235.4813AID2326
67.9K proteinVaccinia virusPotency29.90330.00018.4406100.0000AID720579; AID720580
glucocerebrosidaseHomo sapiens (human)Potency17.78280.01268.156944.6684AID2101
ParkinHomo sapiens (human)Potency18.35640.819914.830644.6684AID720573
arylsulfatase AHomo sapiens (human)Potency0.21331.069113.955137.9330AID720538
IDH1Homo sapiens (human)Potency2.59290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.02510.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency28.18380.540617.639296.1227AID2364; AID2528
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency31.62280.00207.533739.8107AID891
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.04790.01262.451825.0177AID485313
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency30.131323.934123.934123.9341AID1967
cytochrome P450 2C19 precursorHomo sapiens (human)Potency25.11890.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency25.11890.00636.904339.8107AID883
D(1A) dopamine receptorHomo sapiens (human)Potency5.80450.02245.944922.3872AID488982
chromobox protein homolog 1Homo sapiens (human)Potency44.66840.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency8.91250.01789.637444.6684AID588834
flap endonuclease 1Homo sapiens (human)Potency56.23410.133725.412989.1251AID588795
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency19.69490.00378.618923.2809AID2660; AID2666; AID2668
DNA polymerase eta isoform 1Homo sapiens (human)Potency39.81070.100028.9256213.3130AID588591
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency17.78280.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency4.16920.004611.374133.4983AID463097; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency37.68580.031622.3146100.0000AID588579
survival motor neuron protein isoform dHomo sapiens (human)Potency17.78280.125912.234435.4813AID1458
M-phase phosphoprotein 8Homo sapiens (human)Potency39.81070.177824.735279.4328AID488949
lamin isoform A-delta10Homo sapiens (human)Potency17.03900.891312.067628.1838AID1459; AID1487
neuropeptide S receptor isoform AHomo sapiens (human)Potency12.58930.015812.3113615.5000AID1461
Alpha-synucleinHomo sapiens (human)Potency20.32740.56239.398525.1189AID652106
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency25.11890.00638.235039.8107AID883
Guanine nucleotide-binding protein GHomo sapiens (human)Potency50.11871.995325.532750.1187AID624288
TAR DNA-binding protein 43Homo sapiens (human)Potency7.94331.778316.208135.4813AID652104
Ataxin-2Homo sapiens (human)Potency39.81070.011912.222168.7989AID588378
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 2C8Homo sapiens (human)IC50 (µMol)0.00080.00081.88487.9000AID296812
Fatty acid-binding protein, liverMus musculus (house mouse)Ki0.99000.02100.34832.0000AID1802031
Androgen receptorRattus norvegicus (Norway rat)Ki0.00070.00031.21858.9270AID482751
Cannabinoid receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.00400.00020.660910.0000AID625579
Cannabinoid receptor 1Rattus norvegicus (Norway rat)Ki0.00140.00020.566510.0000AID238320
Cannabinoid receptor 1Homo sapiens (human)IC50 (µMol)0.00420.00010.275310.0000AID1285621; AID1336314; AID1546672; AID296812; AID304978; AID310024; AID323698; AID346409; AID464691; AID49169; AID49170; AID751892; AID752253
Cannabinoid receptor 1Homo sapiens (human)Ki0.00260.00010.50779.6000AID1127482; AID1186019; AID1402348; AID1402350; AID1416642; AID1546672; AID1799559; AID1830623; AID1847540; AID1853934; AID1893487; AID258587; AID346409; AID417013; AID482750; AID49298; AID49316; AID502210; AID537909; AID569312; AID579497; AID620178; AID706450; AID731350; AID751892
Cannabinoid receptor 2 Homo sapiens (human)IC50 (µMol)0.00280.00081.58409.8000AID1626206; AID296813; AID310022; AID323697
Cannabinoid receptor 2 Homo sapiens (human)Ki0.00500.00000.415610.0000AID1057093; AID1127483; AID1186020; AID1318549; AID1402349; AID1402351; AID1416639; AID1799559; AID1853935; AID1893488; AID258588; AID259197; AID326577; AID361962; AID417016; AID482751; AID49842; AID502212; AID537910; AID550007; AID569313; AID579498; AID620177; AID706449; AID731349; AID764557; AID764558
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.01300.00000.965010.0000AID258587
N-arachidonyl glycine receptorHomo sapiens (human)IC50 (µMol)5.99005.99005.99005.9900AID750734
G-protein coupled bile acid receptor 1Homo sapiens (human)Ki0.00140.00141.59915.6100AID731349
Cannabinoid receptor 2Rattus norvegicus (Norway rat)IC50 (µMol)0.00210.00210.30900.8200AID323698
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cytochrome P450 1A2Homo sapiens (human)EC50 (µMol)0.00030.00030.20692.0000AID296814
Cytochrome P450 2E1Homo sapiens (human)EC50 (µMol)0.00030.00030.00960.0279AID296816
Cytochrome P450 3A4Homo sapiens (human)EC50 (µMol)0.00030.00010.23283.2000AID296814
Glutamate receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.05310.00411.89638.7000AID257800; AID259201
Glutamate receptor 2Rattus norvegicus (Norway rat)EC50 (µMol)0.05310.00411.62517.6000AID257800; AID259201
Glutamate receptor 3Rattus norvegicus (Norway rat)EC50 (µMol)0.05310.00411.17063.5000AID257800; AID259201
Glutamate receptor 4Rattus norvegicus (Norway rat)EC50 (µMol)0.05310.00411.13393.5000AID257800; AID259201
Cannabinoid receptor 1Rattus norvegicus (Norway rat)EC50 (µMol)0.03360.00020.19211.9953AID1399863; AID1581419; AID1709177; AID1709178; AID257800; AID362454
Cannabinoid receptor 1Homo sapiens (human)EC50 (µMol)0.01320.00010.12752.2400AID1181922; AID1185848; AID1186023; AID1186771; AID1198056; AID1234243; AID1234351; AID1273384; AID1350536; AID1360057; AID1454515; AID1491457; AID1564086; AID1573476; AID1573478; AID1576615; AID1581432; AID1662651; AID1719532; AID1719536; AID1729867; AID1744361; AID1744385; AID1782732; AID1816561; AID1830625; AID1847544; AID1853936; AID1853940; AID1901233; AID1901235; AID296814; AID304980; AID361951; AID362446; AID362450; AID412395; AID502211; AID537902; AID579493; AID620180; AID656259; AID693653; AID706452; AID731348
Cannabinoid receptor 1Homo sapiens (human)Kd0.00160.00010.00210.0044AID1460824; AID1802434
Cytochrome P450 2C19Homo sapiens (human)EC50 (µMol)0.00030.00030.00600.0123AID296814
Cannabinoid receptor 2 Homo sapiens (human)EC50 (µMol)0.03020.00030.15173.2800AID1181917; AID1185850; AID1186021; AID1198057; AID1234244; AID1234352; AID1350537; AID1360059; AID1399864; AID1404266; AID1454516; AID1491458; AID1564089; AID1576617; AID1709179; AID1719534; AID1719538; AID1729869; AID1744363; AID1744381; AID1744386; AID1782733; AID1816562; AID1847545; AID1852964; AID1852966; AID1853937; AID1853941; AID1893479; AID1893481; AID259201; AID296816; AID310025; AID323699; AID326579; AID361954; AID362447; AID362451; AID411516; AID550009; AID620181; AID693652; AID706451; AID728643; AID731347; AID733442; AID768749; AID781166
Cannabinoid receptor 2 Homo sapiens (human)Kd0.00060.00060.07950.1585AID1460825
Cannabinoid receptor 1Mus musculus (house mouse)EC50 (µMol)0.15850.15850.28110.5420AID304980
Transient receptor potential cation channel subfamily V member 1Homo sapiens (human)EC50 (µMol)0.01000.00051.06746.3096AID353804
Cannabinoid receptor 2Rattus norvegicus (Norway rat)EC50 (µMol)0.00030.00030.06660.3150AID362455
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Cannabinoid receptor 1Homo sapiens (human)Kb0.09300.00070.38172.2000AID1845610
Cannabinoid receptor 2 Homo sapiens (human)EC (µMol)0.02330.02330.02330.0233AID708959
Cannabinoid receptor 2 Homo sapiens (human)Kb0.01000.01000.01000.0100AID1845611
G-protein coupled receptor 55Homo sapiens (human)Kb1.89001.89001.89001.8900AID731342
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (227)

Processvia Protein(s)Taxonomy
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 2E1Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2E1Homo sapiens (human)
steroid metabolic processCytochrome P450 2E1Homo sapiens (human)
response to bacteriumCytochrome P450 2E1Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2E1Homo sapiens (human)
carbon tetrachloride metabolic processCytochrome P450 2E1Homo sapiens (human)
benzene metabolic processCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol metabolic processCytochrome P450 2E1Homo sapiens (human)
halogenated hydrocarbon metabolic processCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2E1Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2E1Homo sapiens (human)
lipid hydroxylationCytochrome P450 3A4Homo sapiens (human)
lipid metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid catabolic processCytochrome P450 3A4Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 3A4Homo sapiens (human)
steroid metabolic processCytochrome P450 3A4Homo sapiens (human)
cholesterol metabolic processCytochrome P450 3A4Homo sapiens (human)
androgen metabolic processCytochrome P450 3A4Homo sapiens (human)
estrogen metabolic processCytochrome P450 3A4Homo sapiens (human)
alkaloid catabolic processCytochrome P450 3A4Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 3A4Homo sapiens (human)
calcitriol biosynthetic process from calciolCytochrome P450 3A4Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D metabolic processCytochrome P450 3A4Homo sapiens (human)
vitamin D catabolic processCytochrome P450 3A4Homo sapiens (human)
retinol metabolic processCytochrome P450 3A4Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 3A4Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 3A4Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 3A4Homo sapiens (human)
oxidative demethylationCytochrome P450 3A4Homo sapiens (human)
lipid hydroxylationCytochrome P450 2C8Homo sapiens (human)
organic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C8Homo sapiens (human)
steroid metabolic processCytochrome P450 2C8Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C8Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C8Homo sapiens (human)
retinol metabolic processCytochrome P450 2C8Homo sapiens (human)
retinoic acid metabolic processCytochrome P450 2C8Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C8Homo sapiens (human)
oxidative demethylationCytochrome P450 2C8Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C8Homo sapiens (human)
positive regulation of acute inflammatory response to antigenic stimulusCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
spermatogenesisCannabinoid receptor 1Homo sapiens (human)
axonal fasciculationCannabinoid receptor 1Homo sapiens (human)
response to nutrientCannabinoid receptor 1Homo sapiens (human)
memoryCannabinoid receptor 1Homo sapiens (human)
positive regulation of neuron projection developmentCannabinoid receptor 1Homo sapiens (human)
negative regulation of serotonin secretionCannabinoid receptor 1Homo sapiens (human)
positive regulation of fever generationCannabinoid receptor 1Homo sapiens (human)
negative regulation of fatty acid beta-oxidationCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, GABAergicCannabinoid receptor 1Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 1Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 1Homo sapiens (human)
negative regulation of dopamine secretionCannabinoid receptor 1Homo sapiens (human)
response to nicotineCannabinoid receptor 1Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 1Homo sapiens (human)
response to cocaineCannabinoid receptor 1Homo sapiens (human)
glucose homeostasisCannabinoid receptor 1Homo sapiens (human)
positive regulation of apoptotic processCannabinoid receptor 1Homo sapiens (human)
response to ethanolCannabinoid receptor 1Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 1Homo sapiens (human)
negative regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
positive regulation of blood pressureCannabinoid receptor 1Homo sapiens (human)
regulation of insulin secretionCannabinoid receptor 1Homo sapiens (human)
regulation of synaptic transmission, glutamatergicCannabinoid receptor 1Homo sapiens (human)
maternal process involved in female pregnancyCannabinoid receptor 1Homo sapiens (human)
regulation of feeding behaviorCannabinoid receptor 1Homo sapiens (human)
regulation of penile erectionCannabinoid receptor 1Homo sapiens (human)
retrograde trans-synaptic signaling by endocannabinoidCannabinoid receptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationCannabinoid receptor 1Homo sapiens (human)
trans-synaptic signaling by endocannabinoid, modulating synaptic transmissionCannabinoid receptor 1Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 1Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 1Homo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
response to amphetamineCannabinoid receptor 2 Homo sapiens (human)
inflammatory responseCannabinoid receptor 2 Homo sapiens (human)
immune responseCannabinoid receptor 2 Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerCannabinoid receptor 2 Homo sapiens (human)
leukocyte chemotaxisCannabinoid receptor 2 Homo sapiens (human)
negative regulation of synaptic transmission, GABAergicCannabinoid receptor 2 Homo sapiens (human)
response to lipopolysaccharideCannabinoid receptor 2 Homo sapiens (human)
negative regulation of mast cell activationCannabinoid receptor 2 Homo sapiens (human)
cannabinoid signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
negative regulation of action potentialCannabinoid receptor 2 Homo sapiens (human)
regulation of metabolic processCannabinoid receptor 2 Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayCannabinoid receptor 2 Homo sapiens (human)
calcium ion homeostasisAlpha-synucleinHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIAlpha-synucleinHomo sapiens (human)
microglial cell activationAlpha-synucleinHomo sapiens (human)
positive regulation of receptor recyclingAlpha-synucleinHomo sapiens (human)
positive regulation of neurotransmitter secretionAlpha-synucleinHomo sapiens (human)
negative regulation of protein kinase activityAlpha-synucleinHomo sapiens (human)
fatty acid metabolic processAlpha-synucleinHomo sapiens (human)
neutral lipid metabolic processAlpha-synucleinHomo sapiens (human)
phospholipid metabolic processAlpha-synucleinHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
mitochondrial membrane organizationAlpha-synucleinHomo sapiens (human)
adult locomotory behaviorAlpha-synucleinHomo sapiens (human)
response to xenobiotic stimulusAlpha-synucleinHomo sapiens (human)
response to iron(II) ionAlpha-synucleinHomo sapiens (human)
regulation of phospholipase activityAlpha-synucleinHomo sapiens (human)
negative regulation of platelet-derived growth factor receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
regulation of glutamate secretionAlpha-synucleinHomo sapiens (human)
regulation of dopamine secretionAlpha-synucleinHomo sapiens (human)
synaptic vesicle exocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle primingAlpha-synucleinHomo sapiens (human)
regulation of transmembrane transporter activityAlpha-synucleinHomo sapiens (human)
negative regulation of microtubule polymerizationAlpha-synucleinHomo sapiens (human)
receptor internalizationAlpha-synucleinHomo sapiens (human)
protein destabilizationAlpha-synucleinHomo sapiens (human)
response to magnesium ionAlpha-synucleinHomo sapiens (human)
negative regulation of transporter activityAlpha-synucleinHomo sapiens (human)
response to lipopolysaccharideAlpha-synucleinHomo sapiens (human)
negative regulation of monooxygenase activityAlpha-synucleinHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationAlpha-synucleinHomo sapiens (human)
response to type II interferonAlpha-synucleinHomo sapiens (human)
cellular response to oxidative stressAlpha-synucleinHomo sapiens (human)
SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
positive regulation of SNARE complex assemblyAlpha-synucleinHomo sapiens (human)
regulation of locomotionAlpha-synucleinHomo sapiens (human)
dopamine biosynthetic processAlpha-synucleinHomo sapiens (human)
mitochondrial ATP synthesis coupled electron transportAlpha-synucleinHomo sapiens (human)
regulation of macrophage activationAlpha-synucleinHomo sapiens (human)
positive regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
negative regulation of neuron apoptotic processAlpha-synucleinHomo sapiens (human)
positive regulation of endocytosisAlpha-synucleinHomo sapiens (human)
negative regulation of exocytosisAlpha-synucleinHomo sapiens (human)
positive regulation of exocytosisAlpha-synucleinHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityAlpha-synucleinHomo sapiens (human)
synaptic vesicle endocytosisAlpha-synucleinHomo sapiens (human)
synaptic vesicle transportAlpha-synucleinHomo sapiens (human)
positive regulation of inflammatory responseAlpha-synucleinHomo sapiens (human)
regulation of acyl-CoA biosynthetic processAlpha-synucleinHomo sapiens (human)
protein tetramerizationAlpha-synucleinHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolAlpha-synucleinHomo sapiens (human)
neuron apoptotic processAlpha-synucleinHomo sapiens (human)
dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of dopamine uptake involved in synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of serotonin uptakeAlpha-synucleinHomo sapiens (human)
regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
negative regulation of norepinephrine uptakeAlpha-synucleinHomo sapiens (human)
excitatory postsynaptic potentialAlpha-synucleinHomo sapiens (human)
long-term synaptic potentiationAlpha-synucleinHomo sapiens (human)
positive regulation of inositol phosphate biosynthetic processAlpha-synucleinHomo sapiens (human)
negative regulation of thrombin-activated receptor signaling pathwayAlpha-synucleinHomo sapiens (human)
response to interleukin-1Alpha-synucleinHomo sapiens (human)
cellular response to copper ionAlpha-synucleinHomo sapiens (human)
cellular response to epinephrine stimulusAlpha-synucleinHomo sapiens (human)
positive regulation of protein serine/threonine kinase activityAlpha-synucleinHomo sapiens (human)
supramolecular fiber organizationAlpha-synucleinHomo sapiens (human)
negative regulation of mitochondrial electron transport, NADH to ubiquinoneAlpha-synucleinHomo sapiens (human)
positive regulation of glutathione peroxidase activityAlpha-synucleinHomo sapiens (human)
positive regulation of hydrogen peroxide catabolic processAlpha-synucleinHomo sapiens (human)
regulation of synaptic vesicle recyclingAlpha-synucleinHomo sapiens (human)
regulation of reactive oxygen species biosynthetic processAlpha-synucleinHomo sapiens (human)
positive regulation of protein localization to cell peripheryAlpha-synucleinHomo sapiens (human)
negative regulation of chaperone-mediated autophagyAlpha-synucleinHomo sapiens (human)
regulation of presynapse assemblyAlpha-synucleinHomo sapiens (human)
amyloid fibril formationAlpha-synucleinHomo sapiens (human)
synapse organizationAlpha-synucleinHomo sapiens (human)
chemical synaptic transmissionAlpha-synucleinHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
renal water homeostasisGuanine nucleotide-binding protein GHomo sapiens (human)
G protein-coupled receptor signaling pathwayGuanine nucleotide-binding protein GHomo sapiens (human)
regulation of insulin secretionGuanine nucleotide-binding protein GHomo sapiens (human)
cellular response to glucagon stimulusGuanine nucleotide-binding protein GHomo sapiens (human)
negative regulation of protein phosphorylationTAR DNA-binding protein 43Homo sapiens (human)
mRNA processingTAR DNA-binding protein 43Homo sapiens (human)
RNA splicingTAR DNA-binding protein 43Homo sapiens (human)
negative regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
regulation of protein stabilityTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of insulin secretionTAR DNA-binding protein 43Homo sapiens (human)
response to endoplasmic reticulum stressTAR DNA-binding protein 43Homo sapiens (human)
positive regulation of protein import into nucleusTAR DNA-binding protein 43Homo sapiens (human)
regulation of circadian rhythmTAR DNA-binding protein 43Homo sapiens (human)
regulation of apoptotic processTAR DNA-binding protein 43Homo sapiens (human)
negative regulation by host of viral transcriptionTAR DNA-binding protein 43Homo sapiens (human)
rhythmic processTAR DNA-binding protein 43Homo sapiens (human)
regulation of cell cycleTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA destabilizationTAR DNA-binding protein 43Homo sapiens (human)
3'-UTR-mediated mRNA stabilizationTAR DNA-binding protein 43Homo sapiens (human)
nuclear inner membrane organizationTAR DNA-binding protein 43Homo sapiens (human)
amyloid fibril formationTAR DNA-binding protein 43Homo sapiens (human)
regulation of gene expressionTAR DNA-binding protein 43Homo sapiens (human)
CD8-positive, alpha-beta intraepithelial T cell differentiationN-arachidonyl glycine receptorHomo sapiens (human)
CD8-positive, gamma-delta intraepithelial T cell differentiationN-arachidonyl glycine receptorHomo sapiens (human)
negative regulation of leukocyte chemotaxisN-arachidonyl glycine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayN-arachidonyl glycine receptorHomo sapiens (human)
negative regulation of tumor necrosis factor productionN-arachidonyl glycine receptorHomo sapiens (human)
positive regulation of Rho protein signal transductionN-arachidonyl glycine receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayN-arachidonyl glycine receptorHomo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IITransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
fever generationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
microglial cell activationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
diet induced thermogenesisTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
peptide secretionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of systemic arterial blood pressureTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
lipid metabolic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
chemosensory behaviorTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of heart rateTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of mitochondrial membrane potentialTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
glutamate secretionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to heatTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of apoptotic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
response to peptide hormoneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
positive regulation of nitric oxide biosynthetic processTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
behavioral response to painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
sensory perception of mechanical stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of temperature stimulus involved in thermoceptionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of temperature stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
excitatory postsynaptic potentialTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
smooth muscle contraction involved in micturitionTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to alkaloidTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to ATPTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to tumor necrosis factorTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to acidic pHTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to temperature stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
negative regulation of establishment of blood-brain barrierTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium ion import across plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
response to capsazepineTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cellular response to nerve growth factor stimulusTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cell surface bile acid receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled bile acid receptor 1Homo sapiens (human)
cellular response to bile acidG-protein coupled bile acid receptor 1Homo sapiens (human)
positive regulation of cholangiocyte proliferationG-protein coupled bile acid receptor 1Homo sapiens (human)
regulation of bicellular tight junction assemblyG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled bile acid receptor 1Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
G protein-coupled receptor signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
activation of phospholipase C activityG-protein coupled receptor 55Homo sapiens (human)
positive regulation of Rho protein signal transductionG-protein coupled receptor 55Homo sapiens (human)
cannabinoid signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
bone resorptionG-protein coupled receptor 55Homo sapiens (human)
negative regulation of osteoclast differentiationG-protein coupled receptor 55Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeG-protein coupled receptor 55Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (86)

Processvia Protein(s)Taxonomy
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
iron ion bindingCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
4-nitrophenol 2-monooxygenase activityCytochrome P450 2E1Homo sapiens (human)
oxygen bindingCytochrome P450 2E1Homo sapiens (human)
enzyme bindingCytochrome P450 2E1Homo sapiens (human)
heme bindingCytochrome P450 2E1Homo sapiens (human)
Hsp70 protein bindingCytochrome P450 2E1Homo sapiens (human)
Hsp90 protein bindingCytochrome P450 2E1Homo sapiens (human)
aromatase activityCytochrome P450 2E1Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2E1Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2E1Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2E1Homo sapiens (human)
monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
steroid bindingCytochrome P450 3A4Homo sapiens (human)
iron ion bindingCytochrome P450 3A4Homo sapiens (human)
protein bindingCytochrome P450 3A4Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
oxidoreductase activityCytochrome P450 3A4Homo sapiens (human)
oxygen bindingCytochrome P450 3A4Homo sapiens (human)
enzyme bindingCytochrome P450 3A4Homo sapiens (human)
heme bindingCytochrome P450 3A4Homo sapiens (human)
vitamin D3 25-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
caffeine oxidase activityCytochrome P450 3A4Homo sapiens (human)
quinine 3-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
testosterone 6-beta-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1-alpha,25-dihydroxyvitamin D3 23-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 3A4Homo sapiens (human)
aromatase activityCytochrome P450 3A4Homo sapiens (human)
vitamin D 24-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 3A4Homo sapiens (human)
1,8-cineole 2-exo-monooxygenase activityCytochrome P450 3A4Homo sapiens (human)
monooxygenase activityCytochrome P450 2C8Homo sapiens (human)
iron ion bindingCytochrome P450 2C8Homo sapiens (human)
protein bindingCytochrome P450 2C8Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C8Homo sapiens (human)
retinoic acid 4-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C8Homo sapiens (human)
aromatase activityCytochrome P450 2C8Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 2C8Homo sapiens (human)
heme bindingCytochrome P450 2C8Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C8Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 1Homo sapiens (human)
protein bindingCannabinoid receptor 1Homo sapiens (human)
identical protein bindingCannabinoid receptor 1Homo sapiens (human)
G protein-coupled receptor activityCannabinoid receptor 1Homo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
protein bindingCannabinoid receptor 2 Homo sapiens (human)
cannabinoid receptor activityCannabinoid receptor 2 Homo sapiens (human)
fatty acid bindingAlpha-synucleinHomo sapiens (human)
phospholipase D inhibitor activityAlpha-synucleinHomo sapiens (human)
SNARE bindingAlpha-synucleinHomo sapiens (human)
magnesium ion bindingAlpha-synucleinHomo sapiens (human)
transcription cis-regulatory region bindingAlpha-synucleinHomo sapiens (human)
actin bindingAlpha-synucleinHomo sapiens (human)
protein kinase inhibitor activityAlpha-synucleinHomo sapiens (human)
copper ion bindingAlpha-synucleinHomo sapiens (human)
calcium ion bindingAlpha-synucleinHomo sapiens (human)
protein bindingAlpha-synucleinHomo sapiens (human)
phospholipid bindingAlpha-synucleinHomo sapiens (human)
ferrous iron bindingAlpha-synucleinHomo sapiens (human)
zinc ion bindingAlpha-synucleinHomo sapiens (human)
lipid bindingAlpha-synucleinHomo sapiens (human)
oxidoreductase activityAlpha-synucleinHomo sapiens (human)
kinesin bindingAlpha-synucleinHomo sapiens (human)
Hsp70 protein bindingAlpha-synucleinHomo sapiens (human)
histone bindingAlpha-synucleinHomo sapiens (human)
identical protein bindingAlpha-synucleinHomo sapiens (human)
alpha-tubulin bindingAlpha-synucleinHomo sapiens (human)
cysteine-type endopeptidase inhibitor activity involved in apoptotic processAlpha-synucleinHomo sapiens (human)
tau protein bindingAlpha-synucleinHomo sapiens (human)
phosphoprotein bindingAlpha-synucleinHomo sapiens (human)
molecular adaptor activityAlpha-synucleinHomo sapiens (human)
dynein complex bindingAlpha-synucleinHomo sapiens (human)
cuprous ion bindingAlpha-synucleinHomo sapiens (human)
G protein activityGuanine nucleotide-binding protein GHomo sapiens (human)
adenylate cyclase activator activityGuanine nucleotide-binding protein GHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
double-stranded DNA bindingTAR DNA-binding protein 43Homo sapiens (human)
RNA bindingTAR DNA-binding protein 43Homo sapiens (human)
mRNA 3'-UTR bindingTAR DNA-binding protein 43Homo sapiens (human)
protein bindingTAR DNA-binding protein 43Homo sapiens (human)
lipid bindingTAR DNA-binding protein 43Homo sapiens (human)
identical protein bindingTAR DNA-binding protein 43Homo sapiens (human)
pre-mRNA intronic bindingTAR DNA-binding protein 43Homo sapiens (human)
molecular condensate scaffold activityTAR DNA-binding protein 43Homo sapiens (human)
G protein-coupled receptor activityN-arachidonyl glycine receptorHomo sapiens (human)
transmembrane signaling receptor activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
extracellular ligand-gated monoatomic ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
voltage-gated calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
calmodulin bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
ATP bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
chloride channel regulator activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
phosphatidylinositol bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
metal ion bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
phosphoprotein bindingTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
temperature-gated ion channel activityTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
protein bindingG-protein coupled bile acid receptor 1Homo sapiens (human)
bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
G protein-coupled bile acid receptor activityG-protein coupled bile acid receptor 1Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled receptor activityG-protein coupled receptor 55Homo sapiens (human)
cannabinoid receptor activityG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (49)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
mitochondrial inner membraneCytochrome P450 2E1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 2E1Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2E1Homo sapiens (human)
cytoplasmCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 3A4Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 3A4Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C8Homo sapiens (human)
plasma membraneCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
cytoplasmCytochrome P450 2C8Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C8Homo sapiens (human)
plasma membraneGlutamate receptor 1Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrial outer membraneCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
actin cytoskeletonCannabinoid receptor 1Homo sapiens (human)
growth coneCannabinoid receptor 1Homo sapiens (human)
presynaptic membraneCannabinoid receptor 1Homo sapiens (human)
membrane raftCannabinoid receptor 1Homo sapiens (human)
glutamatergic synapseCannabinoid receptor 1Homo sapiens (human)
GABA-ergic synapseCannabinoid receptor 1Homo sapiens (human)
plasma membraneCannabinoid receptor 1Homo sapiens (human)
cytoplasmCannabinoid receptor 1Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
dendriteCannabinoid receptor 2 Homo sapiens (human)
extrinsic component of cytoplasmic side of plasma membraneCannabinoid receptor 2 Homo sapiens (human)
perikaryonCannabinoid receptor 2 Homo sapiens (human)
endoplasmic reticulumCannabinoid receptor 2 Homo sapiens (human)
plasma membraneCannabinoid receptor 2 Homo sapiens (human)
cytoplasmCannabinoid receptor 2 Homo sapiens (human)
platelet alpha granule membraneAlpha-synucleinHomo sapiens (human)
extracellular regionAlpha-synucleinHomo sapiens (human)
extracellular spaceAlpha-synucleinHomo sapiens (human)
nucleusAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
mitochondrionAlpha-synucleinHomo sapiens (human)
lysosomeAlpha-synucleinHomo sapiens (human)
cytosolAlpha-synucleinHomo sapiens (human)
plasma membraneAlpha-synucleinHomo sapiens (human)
cell cortexAlpha-synucleinHomo sapiens (human)
actin cytoskeletonAlpha-synucleinHomo sapiens (human)
membraneAlpha-synucleinHomo sapiens (human)
inclusion bodyAlpha-synucleinHomo sapiens (human)
axonAlpha-synucleinHomo sapiens (human)
growth coneAlpha-synucleinHomo sapiens (human)
synaptic vesicle membraneAlpha-synucleinHomo sapiens (human)
perinuclear region of cytoplasmAlpha-synucleinHomo sapiens (human)
postsynapseAlpha-synucleinHomo sapiens (human)
supramolecular fiberAlpha-synucleinHomo sapiens (human)
protein-containing complexAlpha-synucleinHomo sapiens (human)
cytoplasmAlpha-synucleinHomo sapiens (human)
axon terminusAlpha-synucleinHomo sapiens (human)
neuronal cell bodyAlpha-synucleinHomo sapiens (human)
plasma membraneGuanine nucleotide-binding protein GHomo sapiens (human)
intracellular non-membrane-bounded organelleTAR DNA-binding protein 43Homo sapiens (human)
nucleusTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
perichromatin fibrilsTAR DNA-binding protein 43Homo sapiens (human)
mitochondrionTAR DNA-binding protein 43Homo sapiens (human)
cytoplasmic stress granuleTAR DNA-binding protein 43Homo sapiens (human)
nuclear speckTAR DNA-binding protein 43Homo sapiens (human)
interchromatin granuleTAR DNA-binding protein 43Homo sapiens (human)
nucleoplasmTAR DNA-binding protein 43Homo sapiens (human)
chromatinTAR DNA-binding protein 43Homo sapiens (human)
plasma membraneN-arachidonyl glycine receptorHomo sapiens (human)
membraneN-arachidonyl glycine receptorHomo sapiens (human)
cytoplasmic vesicle membraneN-arachidonyl glycine receptorHomo sapiens (human)
plasma membraneN-arachidonyl glycine receptorHomo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
external side of plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
dendritic spine membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
neuronal cell bodyTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
postsynaptic membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 1Homo sapiens (human)
cytoplasmG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
receptor complexG-protein coupled bile acid receptor 1Homo sapiens (human)
plasma membraneG-protein coupled bile acid receptor 1Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
plasma membraneG-protein coupled receptor 55Homo sapiens (human)
plasma membraneG-protein coupled receptor 55Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (378)

Assay IDTitleYearJournalArticle
AID1346701Human CB1 receptor (Cannabinoid receptors)1995Molecular pharmacology, Sep, Volume: 48, Issue:3
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2006Trends in pharmacological sciences, Jan, Volume: 27, Issue:1
In silico patent searching reveals a new cannabinoid receptor.
AID1346728Human CB2 receptor (Cannabinoid receptors)1995Molecular pharmacology, Sep, Volume: 48, Issue:3
Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors.
AID1346728Human CB2 receptor (Cannabinoid receptors)1999British journal of pharmacology, Feb, Volume: 126, Issue:3
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
AID1346728Human CB2 receptor (Cannabinoid receptors)1996The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
AID1345070Human GPR55 (GPR18, GPR55 and GPR119)2007British journal of pharmacology, Dec, Volume: 152, Issue:7
The orphan receptor GPR55 is a novel cannabinoid receptor.
AID1346701Human CB1 receptor (Cannabinoid receptors)1996The Journal of pharmacology and experimental therapeutics, Sep, Volume: 278, Issue:3
Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands.
AID1346701Human CB1 receptor (Cannabinoid receptors)1999British journal of pharmacology, Feb, Volume: 126, Issue:3
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID747709Agonist activity at CB1 receptor in mouse Neuro2a cells assessed as inhibition of forskolin-stimulated adenylyl cyclase activity at 10 uM after 15 mins by liquid scintillation spectrophotometry2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
AID706452Agonist activity at human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation using [3H]-cAMP after 5 mins by liquid scintillation counter2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
AID731348Agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 5 mins by cAMP-competition binding assay2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
AID1454515Agonist activity at CB1 receptor (unknown origin) expressed in CHO cells co-expressing G-alpha16 incubated for 24 hrs by fluo-4 AM dye based whole-cell calcium mobilization assay
AID310025Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
AID1744361Agonist activity at human CB1 receptor expressing CHO cells co-expressing Galpha16 by calcium mobilization assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID706449Displacement of [3H]CP55,940 from human CB2 receptor expressed in CHO cells after 2 hrs by liquid scintillation counter2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID731341Antagonist activity at human GPR55 expressed in CHO cells assessed as inhibition of LPI-induced beta-arrestin translocation at 10 uM after 90 mins by luminescence assay2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
AID49298Ability to displace [3H]-SR- 141716A binding to human CB1 receptor expressed in CHO cell membranes1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
3-Alkyl-(5,5'-diphenyl)imidazolidineiones as new cannabinoid receptor ligands.
AID274528Displacement of [3H]CP-55940 from CD1 mouse spleen CB2 receptor2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide.
AID1573478Agonist activity at GFP-fused human CB1 receptor assessed as increase in beta-arrestin-2 recruitment by BRET-based luciferase reporter gene assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID524791Antiplasmodial activity against Plasmodium falciparum 7G8 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID731342Antagonist activity at human GPR55 expressed in CHO cells assessed as inhibition of LPI-induced beta-arrestin translocation after 90 mins by luminescence assay2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
AID1127482Binding affinity to human CB1 receptor2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID417013Binding affinity to human cannabinoid CB1 receptor2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
AID1404278Agonist activity at N-terminal HA-tagged human CB1 receptor expressed in HEK293 cells transfected with YFP-Epac-RLuc assessed as decrease in forskolin-stimulated cAMP level at 10 uM by BRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
AID1830625Agonist activity at human CB1 receptor expressed in CHO cell membranes assessed as increase in [35S]GTPgammaS binding incubated for 30 mins by liquid scintillation spectrometry analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
AID620178Displacement of [3H]-CP55940 from human CB1 receptor expressed in CHO cells by liquid scintillation counting2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1845611Displacement of 35S]GTPgammaS from human CB2 receptor assessed as equilibrium binding constant2021Journal of natural products, 01-22, Volume: 84, Issue:1
Phytocannabinoid Pharmacology: Medicinal Properties of
AID620186Kinetic solubility of the compound in 0.01 M phosphate buffered saline at pH 7.4 assessed as maximum solubility2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1234245Agonist activity at CB2R (unknown origin) CHO cells stably expressing Galpha16 assessed as increase in intracellular calcium level by microplate reader based assay relative to CP559402015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
AID1782732Agonist activity at human recombinant CB1 receptor expressed in CHO-K1 cell membrane assessed as increase in GTPgammaS binding pretreated for 30 mins followed by [35S]GTPgammaS addition for 90 mins by [35S]GTP-gammaS binding assay2021European journal of medicinal chemistry, Aug-05, Volume: 220Synthesis and SAR evaluation of coumarin derivatives as potent cannabinoid receptor agonists.
AID361952Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay relative to CP-559402008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
AID1719532Agonist activity at human recombinant cannabinoid CB1 receptor expressed in HEK cells transfected with CNG assessed as decrease in cAMP level measured up to 1 hr by ACTOne membrane potential dye based assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
AID1399866Agonist activity at recombinant human Cb2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP levels relative to CP-559402018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Oximes short-acting CB1 receptor agonists.
AID1491460Selectivity index, ratio of EC50 for CB1 receptor (unknown origin) to EC50 for CB2 receptor (unknown origin)2017European journal of medicinal chemistry, Sep-08, Volume: 137Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
AID550007Displacement of [3H]-CP55940 from human CB2 receptor expressed in CHO cells after 1 hr2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
AID745765Displacement of [3H]-enkephalin from human delta opioid receptor transfected in CHOK1 cells at 10 uM after 60 mins relative to control2013Journal of natural products, 05-24, Volume: 76, Issue:5
Neocosmospora sp.-derived resorcylic acid lactones with in vitro binding affinity for human opioid and cannabinoid receptors.
AID411516Inverse agonist activity at human recombinant CB2 receptor expressed CHO cells membrane by [35S]GTPgamma binding assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
AID361956Agonist activity at human CB2 receptor expressed in CHO cells at 10 uM by [35S]GTPgammaS assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
AID362446Agonist activity at human CB1 receptor expressed in Sf9 cells by GTP-europium binding assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
AID1360059Agonist activity at human CB2 receptor expressed in CHO cell membranes after 90 mins by [35S]GTPgammaS binding assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system.
AID620189Ratio of permeability from apical to basolateral over basolateral to apical side in human Caco2 cells by LC-MS/MS analysis2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID728643Inverse agonist activity at human CB2 receptor expressed in CHO cells assessed as increase in forskolin-induced cAMP production after 45 mins in presence of phosphodiesterase inhibitor RO20-17242013Journal of medicinal chemistry, Mar-14, Volume: 56, Issue:5
Novel triaryl sulfonamide derivatives as selective cannabinoid receptor 2 inverse agonists and osteoclast inhibitors: discovery, optimization, and biological evaluation.
AID1853936Agonist activity at human CB1 receptor expressed in mouse AtT20 cells incubated for 60 mins by FLIPR membrane potential assay
AID1426541Orthosteric agonist activity at CB1 receptor (unknown origin) expressed in HEK293T cell membrane assessed as increase in Gi-protein mediated ERK1/2 phosphorylation at 0.5 uM in presence of G-protein sensitive pertussis toxin incubated for 5 mins by Wester
AID326581Agonist activity at human CB2 receptor expressed in CHO cells at 3 uM by [35S]GTP-gamma-S binding assay2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.
AID1349534Toxicity in Sprague-Dawley rat assessed as decrease in core body temperature at 0.3 mg/kg, po measured after 60 mins by rectal probe method2017ACS medicinal chemistry letters, Dec-14, Volume: 8, Issue:12
Discovery of APD371: Identification of a Highly Potent and Selective CB
AID1893488Displacement of [3H]-CP55,940 from human CB2R expressed in CHO-K1 cell membranes assessed as inhibition constant incubated for 2 hrs by liquid scintillation spectrometry2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
AID1454518Ratio of EC50 for agonist activity at CB1 receptor (unknown origin) expressed in CHO cells to EC50 for agonist activity at CB2 receptor (unknown origin) expressed in CHO cells
AID1847544Agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 15 mins followed by forskolin stimulation and measured after 15 mins by HTRF assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID764557Displacement of [3H]-SR141716A from human CB1 receptor expressed in CHO membranes after 1 hr by liquid scintillation counting2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.
AID1211515Activation of CB1 receptor in B6SJL mouse brain membrane assessed as [35S]-GTPgammaS binding at 10 uM after 30 mins by liquid scintillation spectrophotometric analysis in presence of O-20502012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID502211Agonist activity at human recombinant CB1 receptor expressed in CHO cells assessed as effect on CP-55940 induced PLA2 activation by [3H]arachidonic acid release assay2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.
AID1127483Binding affinity to human CB2 receptor2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1491459Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells assessed as induction of calcium mobilization by fluo-4 AM dye-based fluorescence assay relative to CP559402017European journal of medicinal chemistry, Sep-08, Volume: 137Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
AID1729867Agonist activity at human CB1 expressed in mouse AtT20 cells assessed as activation of G-protein gated inwardly rectifying K+ channels measured every 2 sec for 2 mins by FLIPR membrane potential assay2021European journal of medicinal chemistry, Jan-15, Volume: 210The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
AID1782733Agonist activity at human recombinant CB2 receptor expressed in CHO-K1 cell membrane assessed as increase in GTPgammaS binding pretreated for 30 mins followed by [35S]GTPgammaS addition for 90 mins by [35S]GTP-gammaS binding assay2021European journal of medicinal chemistry, Aug-05, Volume: 220Synthesis and SAR evaluation of coumarin derivatives as potent cannabinoid receptor agonists.
AID745767Displacement of [3H]-U-69593 from human kappa opioid receptor transfected in CHOK1 cells at 10 uM after 60 mins relative to control2013Journal of natural products, 05-24, Volume: 76, Issue:5
Neocosmospora sp.-derived resorcylic acid lactones with in vitro binding affinity for human opioid and cannabinoid receptors.
AID257800Displacement of [35S]GTP-gamma-S from rat cerebellar CB1 receptor2006Journal of medicinal chemistry, Jan-26, Volume: 49, Issue:2
3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
AID482750Binding affinity to cannabinoid CB1 receptor2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Emerging targets in osteoporosis disease modification.
AID751892Binding affinity to human CB1 receptor by radioligand displacement assay2013European journal of medicinal chemistry, May, Volume: 63Synthesis and structure-activity relationship studies in serotonin 5-HT(1A) receptor agonists based on fused pyrrolidone scaffolds.
AID1744362Agonist activity at human CB1 receptor expressing CHO cells co-expressing Galpha16 by calcium mobilization assay relative to CP559402021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID1360057Agonist activity at human CB1 receptor expressed in CHO cell membranes after 90 mins by [35S]GTPgammaS binding assay2018European journal of medicinal chemistry, Jun-25, Volume: 154Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system.
AID1893478Displacement of [3H]-CP55,940 from human CB1R expressed in CHO-K1 cell membranes incubated for 2 hrs by liquid scintillation spectrometry relative to CP55,9402022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
AID259197Displacement of [3H]CP-55940 from human CB2 receptor2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
AID273078Binding affinity to human CB1 receptor2006Journal of medicinal chemistry, Oct-05, Volume: 49, Issue:20
Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
AID1847539Agonist activity at recombinant human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation by measuring maximum efficacy preincubated for 15 mins followed by forskolin stimulation and measured after 15 mins by 2021European journal of medicinal chemistry, Dec-15, Volume: 226Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID1729869Agonist activity at human CB2 expressed in mouse AtT20 cells assessed as activation of G-protein gated inwardly rectifying K+ channels measured every 2 sec for 2 mins by FLIPR membrane potential assay2021European journal of medicinal chemistry, Jan-15, Volume: 210The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
AID1273384Positive allosteric modulator activity at human CB1R expressed in CHO cells assessed as enhanced binding of [3H]CP55,940 after 60 mins by liquid scintillation spectrometric analysis2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).
AID1360058Agonist activity at human CB1 receptor expressed in CHO cell membranes after 90 mins by [35S]GTPgammaS binding assay relative to control2018European journal of medicinal chemistry, Jun-25, Volume: 154Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system.
AID1709180Agonist activity at human CB2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP level at 500 nM stimulated for 30 mins followed by Eu-cAMP tracer addition and measured after 60 mins relative to control2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Oxa-adamantyl cannabinoids.
AID49169Ability to displace [3H]-SR- 141716A binding to human CB1 receptor expressed in CHO cell membranes in absence of agonist 5''-guanylyimidodiphosphate1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
3-Alkyl-(5,5'-diphenyl)imidazolidineiones as new cannabinoid receptor ligands.
AID1186023Partial agonist activity at human cannabinoid CB1 receptor expressed in CHO-K1 cells assessed as [S35]GTPgammaS binding by scintillation counting2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID1719537Agonist activity at cannabinoid CB1 receptor in human U2OS cells assessed as emission ratio using CCF4/AM as substrate preincubated for 5 hrs followed by substrate addition and measured after 2 hrs by Tango assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
AID411517Inverse agonist activity at human recombinant CB2 receptor expressed CHO cells membrane by [35S]GTPgamma binding assay relative to 2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
AID1573477Agonist activity at GFP-fused human CB1 receptor assessed as increase in cAMP accumulation after 1 hr by FRET assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID610906Binding affinity at human CB2 receptor expressed in CHO-K1 cells at 10 uM2011Journal of natural products, Jul-22, Volume: 74, Issue:7
Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.
AID502210Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in CHO cells2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.
AID569312Displacement of [3H]CP 55940 from human CB1 receptor in cell free system2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
AID1404281Effect on forskolin-stimulated cAMP level in HEK293 cells at 1 uM by BRET assay relative to control2018European journal of medicinal chemistry, Feb-10, Volume: 145Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
AID550009Agonist activity at human CB2 receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
AID731349Displacement of [3H]CP55,940 from recombinant human CB2 receptor expressed in CHO cells after 2 hrs by liquid scintillation counting2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
AID1852965Agonist activity at human CB2 receptor expressed in CHO cells assessed as inhibition of accumulation of forskolin-stimulated cAMP level by measuring maximum activation incubated for 35 mins by chemiluminescence based assay relative to control2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Pyrazolidine Carboxamide Analogs as Selective Agonists of the Cannabinoid 2 Receptor.
AID361951Agonist activity at human CB1 receptor expressed in CHO cells by [35S]GTPgammaS assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
AID1626207Agonist activity at human CB2 receptor expressed in HEK293 cell membranes assessed as induction of [35S]-GTPgammaS binding after 60 mins by liquid scintillation spectrometric method2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
AID1234246Selectivity index, ratio of EC50 for CB1R (unknown origin) CHO cells stably expressing Galpha16 to EC50 for CB2R (unknown origin) CHO cells stably expressing Galpha162015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
AID1853941Agonist activity at CB2 receptor (unknown origin) expressed in human HEK293T cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment using furimazine as substrate by Nano-Glo live cell reagent assay
AID524794Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1853942Agonist activity at CB1 receptor (unknown origin) expressed in human HEK293T cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment by measuring maximal luminescence using furimazine as substrate at 100 uM by Nano-Glo live cell reagent
AID238321Binding affinity for cannabinoid receptor 22005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID1399864Agonist activity at recombinant human Cb2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP levels2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Oximes short-acting CB1 receptor agonists.
AID1201272Agonist activity at rat CB1 receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 60 mins2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
3'-functionalized adamantyl cannabinoid receptor probes.
AID296816Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as reversal of forskolin-evoked cAMP accumulation2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
AID1185849Agonist activity at human recombinant CB1 receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding relative to basal level2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
AID620188Apparent permeability from apical to basolateral side in human Caco2 cells by LC-MS/MS analysis2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID296813Displacement of [3H]CP-55940 human CB2 receptor expressed in CHOK1 cells2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
AID768749Agonist activity at CB2 receptor in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP accumulation2013Journal of medicinal chemistry, Sep-12, Volume: 56, Issue:17
The importance of hydrogen bonding and aromatic stacking to the affinity and efficacy of cannabinoid receptor CB2 antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carbox
AID1853943Agonist activity at CB2 receptor (unknown origin) expressed in human HEK293T cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment by measuring maximal luminescence using furimazine as substrate at 100 uM by Nano-Glo live cell reagent
AID1564089Agonist activity at human CB2 receptor expressed in AtT-20 cells measured every 2 secs for 2 mins by FLIPR assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Strategies to develop selective CB
AID537911Antinociceptive effect in iv dosed mouse assessed as increase in tail-flick latency period by tail flick test2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.
AID326578Selectivity for human cloned CB2 receptor over Sprague Dawley rat brain membrane CB1 receptor2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.
AID579498Displacement of [3H]CP55940 from human cannabinoid CB2 receptor expressed in insect Sf9 cells2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
AID1719535Agonist activity at human recombinant cannabinoid CB2 receptor expressed in HEK cells transfected with CNG assessed as decrease in cAMP level measured up to 1 hr by ACTOne membrane potential dye based assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
AID1186022Partial agonist activity at human cannabinoid CB2 receptor expressed in CHO-K1 cells assessed as [S35]GTPgammaS binding by scintillation counting relative to vehicle treated control2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID781166Agonist activity at human recombinant CB2 receptor expressed in CHO cells after 1 hr by [35S]GTPgammaS binding assay2013European journal of medicinal chemistry, Nov, Volume: 69Mastering tricyclic ring systems for desirable functional cannabinoid activity.
AID1426542Orthosteric agonist activity at CB1 receptor (unknown origin) expressed in HEK293T cell membrane assessed as increase in Gi-protein mediated ERK1/2 phosphorylation at 0.5 uM in presence of beta-arrestin1/2 siRNA incubated for 5 mins by Western blot method
AID1744357Antagonist activity at human CB2 receptor expressing CHO cells co-expressing Galpha16 assessed as inhibition of CP55940-induced calcium mobilization pre-incubated for 15 mins before CP55940 addition2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID323700Agonist activity at human recombinant CB2 receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay relative to CP-559402008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
AID610904Binding affinity at human mu opioid receptor expressed in CHO-K1 cells at 10 uM2011Journal of natural products, Jul-22, Volume: 74, Issue:7
Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.
AID1175780Toxicity in rat assessed as reduction in core temperature at 0.3 mg/kg, ip2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.
AID1852966Agonist activity at human CB2 receptor expressed in PathHunter CHO-K1 CNR2 beta-arrestin cells assessed as beta-arrestin recruitment incubated for 3 hrs by plate reader analysis2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Pyrazolidine Carboxamide Analogs as Selective Agonists of the Cannabinoid 2 Receptor.
AID610902Binding affinity at human delta opioid receptor expressed in CHO-K1 cells at 10 uM2011Journal of natural products, Jul-22, Volume: 74, Issue:7
Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.
AID656259Agonist activity at CB1 receptor2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Low brain penetrant CB1 receptor agonists for the treatment of neuropathic pain.
AID1709177Agonist activity at rat brain CB1 receptor assessed as decrease in forskolin-stimulated cAMP level stimulated for 30 mins followed by Eu-cAMP tracer addition and measured after 60 mins2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Oxa-adamantyl cannabinoids.
AID1816561Agonist activity at 3xHA tagged human CB1 receptor expressed in CHO-K1 cells assessed as reduction in forskolin-stimulated cAMP accumulation incubated for 30 mins by cAMP assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists.
AID1546672Displacement of [3H]CP55940 from human CB1 receptor incubated for 30 mins by scintillation counting method2020Journal of natural products, 01-24, Volume: 83, Issue:1
Isolation of a High-Affinity Cannabinoid for the Human CB1 Receptor from a Medicinal
AID432348Agonist activity at human recombinant CB1 receptor expressed in CHO cells at 10 uM by FLIPR assay2009Bioorganic & medicinal chemistry letters, Aug-01, Volume: 19, Issue:15
Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis.
AID1127484Selectivity ratio of Ki for human CB1 receptor to Ki for human CB2 receptor2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
AID1853940Agonist activity at CB1 receptor (unknown origin) expressed in human HEK293T cells co-expressing beta-arrestin2 assessed as beta-arrestin2 recruitment using furimazine as substrate by Nano-Glo live cell reagent assay
AID1564086Agonist activity at human CB1 receptor expressed in AtT-20 cells measured every 2 secs for 2 mins by FLIPR assay2019European journal of medicinal chemistry, Oct-15, Volume: 180Strategies to develop selective CB
AID417014Displacement of [3H]CP-55940 from cannabinoid CB1 receptor in rat brain cortical membrane2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
AID1360060Agonist activity at human CB2 receptor expressed in CHO cell membranes after 90 mins by [35S]GTPgammaS binding assay relative to control2018European journal of medicinal chemistry, Jun-25, Volume: 154Polypharmacological profile of 1,2-dihydro-2-oxo-pyridine-3-carboxamides in the endocannabinoid system.
AID326579Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.
AID362455Agonist activity at rat recombinant CB2 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated intracellular cAMP level2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
AID296815Agonist activity at human CB1 receptor expressed in HEK293 cells assessed as reversal of forskolin-evoked cAMP accumulation relative to CP-559402007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
AID195417Effective concentration required for stimulation of [35S]GTP-gamma-S, binding in rat microsomal membranes1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID1404280Effect on forskolin-stimulated cAMP level in HEK293 cells at 10 uM by BRET assay relative to control2018European journal of medicinal chemistry, Feb-10, Volume: 145Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
AID1581432Agonist activity at human CB1 receptor expressed in CHO cell membranes assessed as increase in G-protein coupling by measuring [35S]GTPgammaS binding after 90 mins in presence of [35S]GTPgammaS by liquid scintillation analysis2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.
AID579493Agonist activity at human cannabinoid CB1 receptor expressed in CHO cells by luciferase reporter gene assay2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
AID1460825Binding affinity to human CB2 receptor expressed in CHOK1 cells2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1404266Agonist activity at N-terminal HA-tagged human CB2 receptor expressed in HEK293 cells transfected with YFP-Epac-RLuc assessed as decrease in forskolin-stimulated cAMP level by BRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
AID1719534Agonist activity at human recombinant cannabinoid CB2 receptor expressed in HEK cells transfected with CNG assessed as decrease in cAMP level measured up to 1 hr by ACTOne membrane potential dye based assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
AID362450Agonist activity at human recombinant CB1 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated intracellular cAMP level2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
AID745766Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHOK1 cells at 10 uM after 60 mins relative to control2013Journal of natural products, 05-24, Volume: 76, Issue:5
Neocosmospora sp.-derived resorcylic acid lactones with in vitro binding affinity for human opioid and cannabinoid receptors.
AID1198056Agonist activity at CB1 receptor (unknown origin) expressed in CHO cells by calcium mobilization assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
AID1230329Displacement of [3H]-CP55940 from human CB2 receptor transfected into HEK293 cells at 10 uM by microplate scintillation counting2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for Human Opioid and Cannabinoid Receptors.
AID502212Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in CHO cells2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.
AID1893479Agonist activity at human CB2 receptor expressed in CHO-K1 cells assessed as inhibition of froskolin-stimulated cAMP accumulation incubated for 90 mins by HitHunter chemiluminescence based assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
AID49316Compound was evaluated for affinity towards human Cannabinoid receptor 1 using [3H]- SR-141716A as radioligand2002Journal of medicinal chemistry, Apr-25, Volume: 45, Issue:9
Exploration of the pharmacophore of 3-alkyl-5-arylimidazolidinediones as new CB(1) cannabinoid receptor ligands and potential antagonists: synthesis, lipophilicity, affinity, and molecular modeling.
AID1853937Agonist activity at human CB2 receptor expressed in mouse AtT20 cells incubated for 60 mins by FLIPR membrane potential assay
AID258587Displacement of [3H]CP-55940 from human recombinant CB1 receptor2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.
AID1853935Displacement of [3H]-CP55940 from N-terminal 3HA-tagged human CB2 receptor expressed in human HEK293-EBNA cells incubated for 60 mins by radioligand competitive binding assay based liquid scintillation counter
AID1901233Agonist activity at N-terminal 3HA-tagged human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured for 30 mins by FRET assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.
AID304981Reversal of agonist activity at CB1 receptor expressed in CHO cells by a [35S]GTP-gamma-S binding assay assessed in presence of 0.1 uM AM251 CB1 antagonist2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
AID1744385Agonist activity at human CB1 receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay based Tango beta-arrestin recruitment method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID1581419Allosteric agonist activity at N-terminal GFP-tagged rat CB1R expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production after 30 min by TR-FRET assay2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.
AID1201277Agonist activity at human CB2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP accumulation incubated for 60 mins2015Journal of medicinal chemistry, Apr-09, Volume: 58, Issue:7
3'-functionalized adamantyl cannabinoid receptor probes.
AID1230328Displacement of [3H]-CP55940 from human CB1 receptor transfected into HEK293 cells at 10 uM by microplate scintillation counting2015Journal of natural products, Jun-26, Volume: 78, Issue:6
Flavonoids from Perovskia atriplicifolia and Their in Vitro Displacement of the Respective Radioligands for Human Opioid and Cannabinoid Receptors.
AID537902Agonist activity at human CB1 receptor transfected in CHO cells after 5 hrs by luciferase reporter gene assay2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.
AID1830623Displacement of [3H]CP55940 from human CB1 receptor expressed in CHO-K1 cell membranes incubated for 60 mins by liquid scintillation spectrometry analysis2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
AID1893489Displacement of [3H]-CP55,940 from human CB2R expressed in CHO-K1 cell membranes incubated for 2 hrs by liquid scintillation spectrophotometry relative to CP55,9402022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
AID1662652Agonist activity at human CB1 receptor expressed in CHO cell membrane assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay relative to control2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity.
AID304980Agonist activity at human recombinant CB1 receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
AID693652Agonist activity at human CB2 receptor transfected in CHO cell membranes by [35S]GTPgammaS binding assay2012European journal of medicinal chemistry, Dec, Volume: 58Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
AID326577Displacement of [3H]CP-55940 from human cloned CB2 receptor2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.
AID706451Agonist activity at human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation using [3H]-cAMP after 5 mins by liquid scintillation counter2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
AID346409Displacement of radiolabeled CP-55940 from human CB1 receptor2008Journal of medicinal chemistry, Nov-27, Volume: 51, Issue:22
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
AID1416639Displacement of [3H]CP55940 from beta-galactosidase reporter fused human CB2 receptor expressed in CHOK1 cell membranes after 1 hr by scintillation spectrometric analysis2017MedChemComm, Aug-01, Volume: 8, Issue:8
Bioisosteric replacement of central 1,2,4-oxadiazole ring of high affinity CB
AID1056660Toxicity in rat assessed as behavioral impairment at 0.5 mg/kg, ip by rotarod test2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
AID353804Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID590961Aqueous solubility of the compound in 25 mM citrate buffer at pH 5 to 5.1 by micro-shake flask method2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.
AID1318548Displacement of [3H]-CP55,940 from CB1 receptor in mouse whole brain membranes after 60 mins by liquid scintillation spectrometry2016European journal of medicinal chemistry, Oct-04, Volume: 121A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.
AID1318549Displacement of [3H]-CP55,940 from human CB2 receptor transfected in CHO cell membranes after 60 mins by liquid scintillation spectrometry2016European journal of medicinal chemistry, Oct-04, Volume: 121A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2',4'-dichlorophenyl)-N-piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide and analogue derivatives.
AID1744364Agonist activity at human CB2 receptor expressing CHO cells co-expressing Galpha16 by calcium mobilization assay relative to CP559402021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID550006Displacement of [3H]-SR141716A from human CB1 receptor expressed in CHO cells after 1 hr2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
AID1175781Toxicity in rat assessed as behavioral impairment on locomotion at 0.3 mg/kg, ip2015Bioorganic & medicinal chemistry letters, Jan-15, Volume: 25, Issue:2
Discovery of 1a,2,5,5a-tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalen-4-carboxamides as potent and selective CB2 receptor agonists.
AID569313Displacement of [3H]CP 55940 from human CB2 receptor in cell free system2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
AID1402348Displacement of [3H]CP-55,940 from recombinant human full length CB1 receptor expressed in HEK293 cell membranes after 90 mins by topcount method2018European journal of medicinal chemistry, Jan-01, Volume: 143Bioactive products from singlet oxygen photooxygenation of cannabinoids.
AID323699Agonist activity at human recombinant CB2 receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
AID1234244Agonist activity at CB2R (unknown origin) CHO cells stably expressing Galpha16 assessed as increase in intracellular calcium level by microplate reader based assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
AID708959Agonist activity at human CB2 receptor expressed in CHO cells assessed as reduction in forskolin-induced cAMP accumulation incubated for 45 mins by TR-FRET method based LANCE cAMP assay2012Journal of medicinal chemistry, Nov-26, Volume: 55, Issue:22
Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors.
AID296812Displacement of [3H]CP-55940 from human CB1 receptor expressed in HEK293 cells2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
AID1186024Partial agonist activity at human cannabinoid CB1 receptor expressed in CHO-K1 cells assessed as [S35]GTPgammaS binding by scintillation counting relative to vehicle treated control2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID1853934Displacement of [3H]-CP55940 from human CB1 receptor expressed in human HEK293-EBNA cells incubated for 60 mins by radioligand competitive binding assay based liquid scintillation counter
AID620182Lipophilicity, log D of the compound at pH 7.42011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID590958Aqueous solubility of the compound in water at pH 5.3 to 6.2 by shake flask method2011Bioorganic & medicinal chemistry letters, Apr-15, Volume: 21, Issue:8
Design, synthesis and structure-activity relationships of (indo-3-yl) heterocyclic derivatives as agonists of the CB1 receptor. Discovery of a clinical candidate.
AID747711Displacement of [3H]CP-55940 from mouse brain CB1 receptor at 1 uM after 90 mins by scintillation counting analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
AID610903Binding affinity at human kappa opioid receptor expressed in CHO-K1 cells at 10 uM2011Journal of natural products, Jul-22, Volume: 74, Issue:7
Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.
AID502213Selectivity ratio of Ki for human recombinant CB1 receptor to Ki for human recombinant CB2 receptor2010Bioorganic & medicinal chemistry letters, Sep-01, Volume: 20, Issue:17
Two distinct classes of novel pyrazolinecarboxamides as potent cannabinoid CB1 receptor agonists.
AID620180Agonist activity at human CB1 receptor expressed in CHO cells assessed as stimulation of [3H]-arachidonic acid release2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1893481Agonist activity at human CB2 receptor expressed in CHO-K1 cells assessed as enhancement of beta arrestin-2 recruitment incubated for 90 mins by HitHunter chemiluminescence based assay2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
AID1185848Agonist activity at human recombinant CB1 receptor expressed in CHO cell membranes by [35S]GTPgammaS binding assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
AID412395Inverse agonist activity at human recombinant CB1 receptor expressed CHO cells membrane by [35S]GTPgamma binding assay2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
AID524793Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1181922Agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Galpha i2 assessed as Galpha GTPase activity using [gamma-33P]GTP by scintillation counting2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
AID482751Binding affinity to cannabinoid CB2 receptor2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Emerging targets in osteoporosis disease modification.
AID195418Concentration required for stimulation of [35S]GTP-gamma-S, binding in rat microsomal membranes expressed as Emax1998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID537910Displacement of [3H]-CP55940 from human CB2 expressed in insect Sf9 membranes2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.
AID1211514Activation of CB1 receptor in B6SJL mouse brain membrane assessed as [35S]-GTPgammaS binding at 10 uM after 30 mins by liquid scintillation spectrophotometric analysis2012Drug metabolism and disposition: the biological fate of chemicals, Nov, Volume: 40, Issue:11
Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands.
AID579497Displacement of [3H]CP55940 from human cannabinoid CB1 receptor expressed in insect Sf9 cells2011Bioorganic & medicinal chemistry letters, Mar-15, Volume: 21, Issue:6
Discovery of potent and orally bioavailable heterocycle-based cannabinoid CB1 receptor agonists.
AID1491458Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells assessed as induction of calcium mobilization by fluo-4 AM dye-based fluorescence assay2017European journal of medicinal chemistry, Sep-08, Volume: 137Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
AID1185850Agonist activity at human recombinant CB2 receptor expressed in CHO cell membranes by [35S]GTPgammaS binding assay2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
AID620183Thermodynamic solubility of the compound in phosphate buffer at pH 7.4 after 24 hrs by HPLC analysis2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID524790Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID620177Displacement of [3H]-CP55940 from human CB2 receptor expressed in CHO cells by liquid scintillation counting2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1662651Agonist activity at human CB1 receptor expressed in CHO cell membrane assessed as stimulation of [35S]-GTPgammaS binding incubated for 1 hr by by liquid scintillation counting assay2020Bioorganic & medicinal chemistry, 06-01, Volume: 28, Issue:11
Synthetic bioactive olivetol-related amides: The influence of the phenolic group in cannabinoid receptor activity.
AID731347Agonist activity at recombinant human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 5 mins by cAMP-competition binding assay2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
AID1581420Allosteric agonist activity at N-terminal GFP-tagged rat CB1R expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production by measuring cAMP accumulation at minimal level at higher concentrations after 30 min by TR-FRET assay rela2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.
AID1454516Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells co-expressing G-alpha16 incubated for 24 hrs by fluo-4 AM dye based whole-cell calcium mobilization assay
AID296817Agonist activity at human CB2 receptor expressed in CHOK1 cells assessed as reversal of forskolin-evoked cAMP accumulation relative to CP-559402007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
AID1719538Agonist activity at cannabinoid CB2 receptor in human U2OS cells assessed as induction of beta-arrestin recruitment using CCF4/AM as substrate preincubated for 5 hrs followed by substrate addition and measured after 2 hrs by Tango assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
AID1181919Agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Galpha i2 assessed as Galpha GTPase activity using [gamma-33P]GTP at 100 uM by scintillation counting (Rvb = 0 +/- 3%)2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
AID361955Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay relative to CP-559402008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
AID49170Ability to displace [3H]-SR- 141716A binding to human CB1 receptor expressed in CHO cell membranes in presence of agonist 5'-guanylyimidodiphosphate 50 uM1999Bioorganic & medicinal chemistry letters, Aug-02, Volume: 9, Issue:15
3-Alkyl-(5,5'-diphenyl)imidazolidineiones as new cannabinoid receptor ligands.
AID1234243Agonist activity at CB1R (unknown origin) CHO cells stably expressing Galpha16 assessed as increase in intracellular calcium level by microplate reader based assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Development of Quinoline-2,4(1H,3H)-diones as Potent and Selective Ligands of the Cannabinoid Type 2 Receptor.
AID693655Agonist activity at human CB1 receptor transfected in CHO cell membranes at 0.001 to 30 uM by [35S]GTPgammaS binding assay relative to CP559402012European journal of medicinal chemistry, Dec, Volume: 58Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
AID1454517Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells co-expressing G-alpha16 incubated for 24 hrs by fluo-4 AM dye based whole-cell calcium mobilization assay relative to CP55940
AID706450Displacement of [3H]CP55,940 from human CB1 receptor expressed in CHO cells after 2 hrs by liquid scintillation counter2012Journal of medicinal chemistry, Sep-27, Volume: 55, Issue:18
7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
AID353805Agonist activity at human recombinant TRPV1 expressed in HEK293 cells assessed as increase in intracellular calcium level relative to ionomycin2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes.
AID464691Inverse agonist activity at human cannabinoid CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-stimulated cAMP accumulation after 60 mins2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Discovery of benzhydrylpiperazine derivatives as CB1 receptor inverse agonists via privileged structure-based approach.
AID1185851Agonist activity at human recombinant CB2 receptor expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding relative to basal level2014Bioorganic & medicinal chemistry, Sep-01, Volume: 22, Issue:17
Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
AID1057093Displacement of [3H]CP-55,940 from human recombinant cannabinoid CB2 receptor expressed in CHO cells2013Bioorganic & medicinal chemistry, Dec-01, Volume: 21, Issue:23
Development of fluorinated CB(2) receptor agonists for PET studies.
AID1234351Agonist activity at human CB1 receptor expressed in HEK cells assessed as inhibition of forskolin-induced cAMP accumulation2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors.
AID620187Dissociation constant, pKa of the compound by fast UV-metric method2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID417378Agonist activity at human recombinant cannabinoid CB1 receptor expressed in HEK293 cells assessed as maximal stimulation of GTPgammaS binding at 30 uM by liquid scintillation counting relative to basal level2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
AID1893480Agonist activity at human CB2 receptor expressed in CHO-K1 cells assessed as inhibition of froskolin-stimulated cAMP accumulation at 10 uM incubated for 90 mins by HitHunter chemiluminescence based assay relative to CP55,9402022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
AID1273389Positive allosteric modulator activity at human CB1R expressed in CHO cells assessed as enhanced binding of [3H]CP55,940 after 60 mins by liquid scintillation spectrometric analysis relative to control2016Journal of medicinal chemistry, Jan-14, Volume: 59, Issue:1
Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s).
AID1458808PAM antagonist activity at CB1 receptor in CD-1 mouse cerebellar membranes assessed as increase in [3H]CP55,940 binding after 90 mins relative to control2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Novel Diarylurea Based Allosteric Modulators of the Cannabinoid CB1 Receptor: Evaluation of Importance of 6-Pyrrolidinylpyridinyl Substitution.
AID693654Agonist activity at human CB2 receptor transfected in CHO cell membranes at 0.001 to 10 uM by [35S]GTPgammaS binding assay relative to CP559402012European journal of medicinal chemistry, Dec, Volume: 58Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
AID1893487Displacement of [3H]-CP55,940 from human CB1R expressed in CHO-K1 cell membranes assessed as inhibition constant incubated for 2 hrs by liquid scintillation spectrometry analysis2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
AID693653Agonist activity at human CB1 receptor transfected in CHO cell membranes by [35S]GTPgammaS binding assay2012European journal of medicinal chemistry, Dec, Volume: 58Investigations on the 4-quinolone-3-carboxylic acid motif. 6. Synthesis and pharmacological evaluation of 7-substituted quinolone-3-carboxamide derivatives as high affinity ligands for cannabinoid receptors.
AID258588Displacement of [3H]CP-55940 from human recombinant CB2 receptor2006Bioorganic & medicinal chemistry letters, Jan-01, Volume: 16, Issue:1
New metabolically stable fatty acid amide ligands of cannabinoid receptors: Synthesis and receptor affinity studies.
AID620184Thermodynamic solubility of the compound in phosphate buffer at pH 4 after 24 hrs by HPLC analysis2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID747710Displacement of [3H]CP-55940 from mouse brain CB2 receptor at 1 uM after 90 mins by scintillation counting analysis2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
AID310022Displacement of [3H]CP-55940 form human CB2 receptor expressed in CHO cells2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
AID750734Antagonist activity at human GPR18 transfected in CHO cells assessed as delta9-THC-induced beta-arrestin recruitment incubated 60 mins prior to delta9-THC addition by beta-arrestin translocation assay2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Antagonists for the orphan G-protein-coupled receptor GPR55 based on a coumarin scaffold.
AID259201Effect on [35S]GTP-gamma-S binding to human CB2 receptor2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
AID550010Agonist activity at human CB2 receptor expressed in CHO cells assessed as stimulation of [35S]-GTPgammaS binding relative to basal activity2010Journal of medicinal chemistry, Nov-25, Volume: 53, Issue:22
4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.
AID1901234Agonist activity at N-terminal 3HA-tagged human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation measured for 30 mins by FRET assay relative to control2022European journal of medicinal chemistry, Feb-15, Volume: 230Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.
AID1847540Displacement of [3H]-CP55940 from recombinant human CB1 receptor expressed in CHO cells assessed as inhibition constant incubated for 120 mins by radioligand binding assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID733442Agonist activity at human CB2 receptor expressed in CHO cell membranes assessed as increase in forskolin-stimulated cAMP production after 45 mins by TR-FRET assay2013ACS medicinal chemistry letters, Apr-11, Volume: 4, Issue:4
Trisubstituted Sulfonamides: a New Chemotype for Development of Potent and Selective CB
AID323698Displacement of [3H]CP-55940 from human recombinant CB1 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
AID752253Binding affinity to human CB1 receptor by radioligand displacement assay2013Bioorganic & medicinal chemistry, May-15, Volume: 21, Issue:10
Synthesis and biological evaluation of 2-(5-methyl-4-phenyl-2-oxopyrrolidin-1-yl)-acetamide stereoisomers as novel positive allosteric modulators of sigma-1 receptor.
AID49842Binding affinity to human CB2 cannabinoid receptor using [3H]CP-55940 in HEK293 EBNA transfected cells2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
AID1186020Displacement of [3H]CP55940 from human cannabinoid CB2 receptor expressed in CHO-K1 cells by liquid scintillation counting2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID1402351Agonist activity at recombinant human full length CB2 receptor expressed in HEK293 cell membranes after 2 hrs by [35S]GTP-gammaS binding assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Bioactive products from singlet oxygen photooxygenation of cannabinoids.
AID1845610Displacement of [35S]GTPgammaS from human CB1 assessed as equilibrium binding constant2021Journal of natural products, 01-22, Volume: 84, Issue:1
Phytocannabinoid Pharmacology: Medicinal Properties of
AID195419Effective concentration required for stimulation of [35S]GTP-gamma-S, binding in rat microsomal membranes expressed as log EC501998Journal of medicinal chemistry, Dec-31, Volume: 41, Issue:27
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability.
AID1719539Agonist activity at cannabinoid CB2 receptor in human U2OS cells assessed as emission ratio using CCF4/AM as substrate preincubated for 5 hrs followed by substrate addition and measured after 2 hrs by Tango assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
AID304978Binding affinity to human recombinant CB1 receptor2007Bioorganic & medicinal chemistry letters, Jan-01, Volume: 17, Issue:1
Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
AID569314Selectivity ratio of Ki for human CB1 to Ki for human CB22011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
AID1626206Agonist activity at human CB2 receptor expressed in HEK293 cell membranes assessed as inhibition of forskolin-stimulated cAMP accumulation after 60 mins by HTRF assay2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
AID745763Displacement of [3H]-CP55940 from human recombinant CB1 receptor transfected in HEK293 cells at 10 uM after 90 mins relative to control2013Journal of natural products, 05-24, Volume: 76, Issue:5
Neocosmospora sp.-derived resorcylic acid lactones with in vitro binding affinity for human opioid and cannabinoid receptors.
AID633470Agonist activity at MF1 mouse brain CB1 receptor assessed as induction of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting relative to cannabinoid receptor agonist CP559402011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.
AID49325Binding affinity towards cloned human Cannabinoid receptor 12000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID326576Displacement of [3H]CP-55940 from CB1 receptor in Sprague-Dawley rat brain membrane2008Bioorganic & medicinal chemistry, Jan-01, Volume: 16, Issue:1
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940.
AID1404276Agonist activity at N-terminal HA-tagged human CB2 receptor expressed in HEK293 cells transfected with YFP-Epac-RLuc assessed as decrease in forskolin-stimulated cAMP level at 10 uM by BRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
AID1573534Ratio of EC50 for GFP-fused human CB1 receptor assessed as increase in beta-arrestin-2 recruitment to EC50 for GFP-fused human CB1 receptor assessed as increase in cAMP accumulation2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID310024Displacement of [3H]CP-55940 form human CB1 receptor expressed in CHO cells2007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
AID1719536Agonist activity at cannabinoid CB1 receptor in human U2OS cells assessed as induction of beta-arrestin recruitment using CCF4/AM as substrate preincubated for 5 hrs followed by substrate addition and measured after 2 hrs by Tango assay2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
AID1576617Agonist activity at human CB2-receptor expressed in CHO-K1 cells coexpressing G-alpha16 by Fluo-4-AM dye based calcium mobilization assay2019MedChemComm, Dec-01, Volume: 10, Issue:12
Introducing nitrogen atoms to amidoalkylindoles: potent and selective cannabinoid type 2 receptor agonists with improved aqueous solubility.
AID1729868Agonist activity at human CB1 expressed in mouse AtT20 cells assessed as maximal activation of G-protein gated inwardly rectifying K+ channels measured every 2 sec for 2 mins by FLIPR membrane potential assay relative to control2021European journal of medicinal chemistry, Jan-15, Volume: 210The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
AID1186772Agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Gbeta1gamma2 and RSG4 assessed as degradation of [gamma-33P]GTP at 30 uM after 20 mins by steady-state GTPase assay relative to control2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.
AID1709184Agonist activity at rat CB1 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP level stimulated for 30 mins followed by Eu-cAMP tracer addition and measured after 60 mins2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Oxa-adamantyl cannabinoids.
AID1709179Agonist activity at human CB2 receptor expressed in HEK293 cells assessed as decrease in forskolin-stimulated cAMP level stimulated for 30 mins followed by Eu-cAMP tracer addition and measured after 60 mins2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Oxa-adamantyl cannabinoids.
AID274529Displacement of [3H]CP-55940 from CD1 mouse brain CB1 receptor2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide.
AID1336314Displacement of [3H]CP 55940 from human recombinant CB1 receptor expressed in CHO cells measured after 120 mins by scintillation counting method2017Bioorganic & medicinal chemistry, 01-15, Volume: 25, Issue:2
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH
AID1564088Agonist activity at human CB1 receptor expressed in AtT-20 cells at 1 uM measured every 2 secs for 2 mins by FLIPR assay relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Strategies to develop selective CB
AID362454Agonist activity at rat recombinant CB1 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated intracellular cAMP level2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
AID1198057Agonist activity at CB2 receptor (unknown origin) expressed in CHO cells by calcium mobilization assay2015European journal of medicinal chemistry, Mar-26, Volume: 93Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
AID1744386Agonist activity at human CB2 receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay based Tango beta-arrestin recruitment method2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID1852964Agonist activity at human CB2 receptor expressed in CHO cells assessed as inhibition of accumulation of forskolin-stimulated cAMP level incubated for 35 mins by chemiluminescence based assay2022ACS medicinal chemistry letters, Dec-08, Volume: 13, Issue:12
Pyrazolidine Carboxamide Analogs as Selective Agonists of the Cannabinoid 2 Receptor.
AID1186771Agonist activity at human CB1 receptor expressed in Sf9 cells coexpressing Gbeta1gamma2 and RSG4 assessed as degradation of [gamma-33P]GTP after 20 mins by steady-state GTPase assay2014Bioorganic & medicinal chemistry letters, Sep-01, Volume: 24, Issue:17
Design, synthesis and in vitro evaluation of novel uni- and bivalent ligands for the cannabinoid receptor type 1 with variation of spacer length and structure.
AID620179Selectivity ratio of Ki for human CB2 receptor to Ki for human CB1 receptor2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID259200Effect on human CB2 receptor stimulation by [35S]GTP-gamma-S binding at 10 uM (basal value set at 100%)2006Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1
Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
AID1181917Agonist activity at human CB2 receptor expressed in Sf9 cells coexpressing Galpha i2 assessed as Galpha GTPase activity using [gamma-33P]GTP by scintillation counting2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
AID417376Agonist activity at cannabinoid CB1 receptor in rat brain cortical membrane assessed as maximal stimulation of GTPgammaS binding at 30 uM by liquid scintillation counting relative to basal level2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
AID524795Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1830624Displacement of [3H]CP55940 from human CB1 receptor expressed in CHO-K1 cell membrane assessed as maximum efficacy incubated for 60 mins by liquid scintillation spectrometry analysis relative to control2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
AID1744395Agonist activity at human CB1 receptor expressing CHO cells co-expressing Galpha16 at 10 uM by calcium mobilization assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID1893482Agonist activity at human CB2 receptor expressed in CHO-K1 cells assessed as enhancement of beta arrestin-2 recruitment at 10 uM incubated for 90 mins by HitHunter chemiluminescence based assay relative to CP55,9402022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Design, Synthesis, and Biological Activity of New CB2 Receptor Ligands: from Orthosteric and Allosteric Modulators to Dualsteric/Bitopic Ligands.
AID747708Agonist activity at human CB2 receptor transfected in CHO cells assessed as inhibition of forskolin-stimulated adenylyl cyclase activity at 10 uM after 15 mins by liquid scintillation spectrophotometry2013Journal of medicinal chemistry, Jun-13, Volume: 56, Issue:11
Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
AID362451Agonist activity at human recombinant CB2 receptor expressed in CHO-K1 cells assessed as inhibition of forskolin-stimulated intracellular cAMP level2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
AID1576615Agonist activity at human CB1-receptor expressed in CHO-K1 cells coexpressing G-alpha16 by Fluo-4-AM dye based calcium mobilization assay2019MedChemComm, Dec-01, Volume: 10, Issue:12
Introducing nitrogen atoms to amidoalkylindoles: potent and selective cannabinoid type 2 receptor agonists with improved aqueous solubility.
AID745762Displacement of [3H]-CP55940 from human recombinant CB2 receptor transfected in HEK293 cells at 10 uM after 90 mins relative to control2013Journal of natural products, 05-24, Volume: 76, Issue:5
Neocosmospora sp.-derived resorcylic acid lactones with in vitro binding affinity for human opioid and cannabinoid receptors.
AID764558Displacement of [3H]-CP55,940 from human CB2 receptor expressed in CHO membranes after 1 hr by liquid scintillation counting2013Bioorganic & medicinal chemistry, Sep-01, Volume: 21, Issue:17
3-Carboxamido-5-aryl-isoxazoles as new CB2 agonists for the treatment of colitis.
AID1234352Agonist activity at human CB2 receptor expressed in HEK cells assessed as inhibition of forskolin-induced cAMP accumulation2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Distinct Temporal Fingerprint for Cyclic Adenosine Monophosphate (cAMP) Signaling of Indole-2-carboxamides as Allosteric Modulators of the Cannabinoid Receptors.
AID1830626Agonist activity at human CB1 receptor expressed in CHO cell membranes assessed as increase in [35S]GTPgammaS binding by measuring maximum efficacy incubated for 30 mins by liquid scintillation spectrometry analysis relative to control2021Bioorganic & medicinal chemistry, 11-15, Volume: 50Design, synthesis, and pharmacological profiling of cannabinoid 1 receptor allosteric modulators: Preclinical efficacy of C2-group GAT211 congeners for reducing intraocular pressure.
AID274531Intrinsic activity at CB2 receptor assessed as induction of ERK1/2 phosphorylation in HL60 cells at 100 nM after 10 mins relative to control2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide.
AID1350537Agonist activity at N-terminal FLAG-tagged human CB2 receptor transfected in human HTLA cells assessed as induction of beta-arrestin-recruitment after 8 to 14 hrs by bright-glo luminescence based assay2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID1573476Agonist activity at GFP-fused human CB1 receptor assessed as increase in cAMP accumulation after 1 hr by FRET assay2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID1853939Agonist activity at human CB2 receptor expressed in mouse AtT20 cells assessed as maximal agonist effect by measuring fluorescence at 10 uM incubated for 60 mins by FLIPR membrane potential assay relative to CP55940
AID1719533Agonist activity at human recombinant cannabinoid CB1 receptor expressed in HEK cells transfected with CNG assessed as decrease in cAMP level measured up to 1 hr by ACTOne membrane potential dye based assay relative to control2021Bioorganic & medicinal chemistry, 03-01, Volume: 33Synthesis and biological evaluation of a ring analogs of the selective CB2 inverse agonist SMM-189.
AID49503Binding affinity to CB1 cannabinoid receptor using [3H]WIN-55212-2 in rat cerebellum membranes2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.
AID1399863Agonist activity at recombinant rat Cb1 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP levels2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Oximes short-acting CB1 receptor agonists.
AID361953Agonist activity at human CB1 receptor expressed in CHO cells at 10 uM by [35S]GTPgammaS assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
AID1626211Binding affinity to human serum albumin at 40 uM by surface plasmon resonance method2016Journal of medicinal chemistry, 07-28, Volume: 59, Issue:14
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
AID296814Agonist activity at human CB1 receptor expressed in HEK293 cells assessed as reversal of forskolin-evoked cAMP accumulation2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
AID1404272Agonist activity at N-terminal HA-tagged human CB1 receptor expressed in HEK293 cells transfected with YFP-Epac-RLuc assessed as decrease in forskolin-stimulated cAMP level by BRET assay2018European journal of medicinal chemistry, Feb-10, Volume: 145Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
AID1285621Displacement of [3H]CP 55940 from human recombinant CB1 receptor expressed in CHO cells2016Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.
AID296820Antihyperalgesic activity in rat assessed as reversal of hyperalgesia2007Journal of medicinal chemistry, Aug-09, Volume: 50, Issue:16
Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.
AID1744363Agonist activity at human CB2 receptor expressing CHO cells co-expressing Galpha16 by calcium mobilization assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID417016Displacement of [3H]CP-55940 from human recombinant cannabinoid CB2 receptor expressed in HEK293 cells2009Bioorganic & medicinal chemistry, Apr-01, Volume: 17, Issue:7
Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.
AID633469Agonist activity at MF1 mouse brain CB1 receptor assessed as induction of [35S]GTPgammaS binding after 60 mins by liquid scintillation counting2011Journal of medicinal chemistry, Dec-22, Volume: 54, Issue:24
Resorcinol-sn-glycerol derivatives: novel 2-arachidonoylglycerol mimetics endowed with high affinity and selectivity for cannabinoid type 1 receptor.
AID1460824Binding affinity to human CB1 receptor expressed in CHOK1 cells2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID238320Binding affinity for cannabinoid receptor 12005Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16
The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications.
AID1186019Displacement of [3H]CP55940 from human cannabinoid CB1 receptor expressed in CHO-K1 cells by liquid scintillation counting2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID49851Binding affinity towards cloned human cannabinoid receptor 22000Journal of medicinal chemistry, Jun-15, Volume: 43, Issue:12
A 3D-QSAR study on the structural requirements for binding to CB(1) and CB(2) cannabinoid receptors.
AID1186021Partial agonist activity at human cannabinoid CB2 receptor expressed in CHO-K1 cells assessed as [S35]GTPgammaS binding by scintillation counting2014European journal of medicinal chemistry, Oct-06, Volume: 85One-pot heterogeneous synthesis of Δ(3)-tetrahydrocannabinol analogues and xanthenes showing differential binding to CB(1) and CB(2) receptors.
AID1581433Agonist activity at human CB1 receptor expressed in CHO cell membranes assessed as increase in G-protein coupling by measuring [35S]GTPgammaS binding after 90 mins in presence of [35S]GTPgammaS by liquid scintillation analysis relative to control2020Journal of medicinal chemistry, 01-23, Volume: 63, Issue:2
Application of Fluorine- and Nitrogen-Walk Approaches: Defining the Structural and Functional Diversity of 2-Phenylindole Class of Cannabinoid 1 Receptor Positive Allosteric Modulators.
AID1402349Displacement of [3H]CP-55,940 from recombinant human full length CB2 receptor expressed in HEK293 cell membranes after 90 mins by topcount method2018European journal of medicinal chemistry, Jan-01, Volume: 143Bioactive products from singlet oxygen photooxygenation of cannabinoids.
AID361954Agonist activity at human CB2 receptor expressed in CHO cells by [35S]GTPgammaS assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
AID310026Efficacy at human CB2 receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay relative to CP-559402007Bioorganic & medicinal chemistry letters, Nov-15, Volume: 17, Issue:22
N-Alkylidenearylcarboxamides as new potent and selective CB(2) cannabinoid receptor agonists with good oral bioavailability.
AID1056661Toxicity in rat assessed as induction of hypothermia at 0.5 mg/kg, ip by rotarod test2013Journal of medicinal chemistry, Jul-25, Volume: 56, Issue:14
Selective cannabinoid receptor type 2 (CB2) agonists: optimization of a series of purines leading to the identification of a clinical candidate for the treatment of osteoarthritic pain.
AID537909Displacement of [3H]-CP55940 from human CB1 expressed in insect Sf9 membranes2010Bioorganic & medicinal chemistry letters, Dec-15, Volume: 20, Issue:24
Design, synthesis, and structure-activity relationship study of bicyclic piperazine analogs of indole-3-carboxamides as novel cannabinoid CB1 receptor agonists.
AID1709178Agonist activity at rat brain CB1 receptor assessed as inhibition of forskolin-stimulated cAMP level at 500 nM stimulated for 30 mins followed by Eu-cAMP tracer addition and measured after 60 mins relative to control2021Bioorganic & medicinal chemistry letters, 04-15, Volume: 38Oxa-adamantyl cannabinoids.
AID302381Displacement of [3H]CP-55940 from human CB1 receptor expressed in CHO cells2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
AID362447Agonist activity at human recombinant CB2 receptor expressed in Sf9 cells by GTP-europium binding assay2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.
AID302382Displacement of [3H]CP-55940 from human CB2 receptor expressed in CHO cells2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
AID1402350Agonist activity at recombinant human full length CB1 receptor expressed in HEK293 cell membranes after 2 hrs by [35S]GTP-gammaS binding assay2018European journal of medicinal chemistry, Jan-01, Volume: 143Bioactive products from singlet oxygen photooxygenation of cannabinoids.
AID625579Displacement of [3H]BMS-725519 from rat brain CB1 receptor after 90 mins by scintillation counting2011Bioorganic & medicinal chemistry letters, Nov-15, Volume: 21, Issue:22
Characterization of a novel and selective CB1 antagonist as a radioligand for receptor occupancy studies.
AID412396Inverse agonist activity at human recombinant CB1 receptor expressed CHO cells membrane by [35S]GTPgamma binding assay relative to 2-((1R,2R,5R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl)-5-(2-methyloctan-2-yl)phenol2009Journal of medicinal chemistry, Jan-22, Volume: 52, Issue:2
6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.
AID1198059Selectivity index, ratio of EC50 for CB1 receptor (unknown origin) to EC50 for CB2 receptor (unknown origin)2015European journal of medicinal chemistry, Mar-26, Volume: 93Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
AID1181914Agonist activity at human CB2 receptor expressed in Sf9 cells coexpressing Galpha i2 assessed as Galpha GTPase activity using [gamma-33P]GTP at 100 uM by scintillation counting (Rvb = 0 +/- 1%)2014Bioorganic & medicinal chemistry, Aug-01, Volume: 22, Issue:15
Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB₂R selective benzimidazoles reveal unexpected intrinsic properties.
AID1816562Agonist activity at 3xHA tagged human CB2 receptor expressed in CHO-K1 cells assessed as reduction in forskolin-stimulated cAMP accumulation incubated for 30 mins by cAMP assay2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Novel Functionalized Cannabinoid Receptor Probes: Development of Exceptionally Potent Agonists.
AID620181Agonist activity at human CB2 receptor expressed in CHO cells assessed as increase of forskolin-stimulated cAMP accumulation after 20 mins2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID302384Activity at human CB2 receptor expressed in CHO cells assessed as stimulated [35S]GTP-gamma-S binding relative to control2007Journal of medicinal chemistry, Nov-01, Volume: 50, Issue:22
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
AID620185Kinetic solubility of the compound in 0.01 M phosphate buffered saline at pH 7.4 assessed as minimum solubility2011European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: design, synthesis, structure-activity relationships, physicochemical properties and biological activity.
AID1729870Agonist activity at human CB2 expressed in mouse AtT20 cells assessed as maximal activation of G-protein gated inwardly rectifying K+ channels measured every 2 sec for 2 mins by FLIPR membrane potential assay relative to control2021European journal of medicinal chemistry, Jan-15, Volume: 210The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
AID731350Displacement of [3H]CP55,940 from recombinant human CB1 receptor expressed in CHO cells after 2 hrs by liquid scintillation counting2013ACS medicinal chemistry letters, Jan-10, Volume: 4, Issue:1
Magnolia Extract, Magnolol, and Metabolites: Activation of Cannabinoid CB2 Receptors and Blockade of the Related GPR55.
AID361962Displacement of [3H]CP-55940 from human CB2 receptor expressed in CHOK1 cells by liquid scintillation counting2008Journal of medicinal chemistry, Aug-28, Volume: 51, Issue:16
Design and synthesis of a novel series of N-alkyl isatin acylhydrazone derivatives that act as selective cannabinoid receptor 2 agonists for the treatment of neuropathic pain.
AID1404269Agonist activity at N-terminal HA-tagged human CB2 receptor expressed in HEK293 cells transfected with YFP-Epac-RLuc assessed as decrease in forskolin-stimulated cAMP level by BRET assay relative to control2018European journal of medicinal chemistry, Feb-10, Volume: 145Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
AID1853938Agonist activity at human CB1 receptor expressed in mouse AtT20 cells assessed as maximal agonist effect by measuring fluorescence at 10 uM incubated for 60 mins by FLIPR membrane potential assay relative to CP55940
AID671812Induction of hypothermia in monoiodoacetic acid rat model of osteoarthritic pain at 0.5 mg/kg, ip2012Bioorganic & medicinal chemistry letters, Aug-01, Volume: 22, Issue:15
Discovery and optimization of novel purines as potent and selective CB2 agonists.
AID1744396Induction of receptor desensitization at human CB1 receptor expressing CHO cells co-expressing Galpha16 at 10 uM followed by washing with HBSS buffer upon incubation for 10 mins and restimulated with CP55940 by calcium mobilization assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID323697Displacement of [3H]CP-55940 from human recombinant CB2 receptor expressed in CHO cells2008Bioorganic & medicinal chemistry, Feb-01, Volume: 16, Issue:3
Imine derivatives as new potent and selective CB2 cannabinoid receptor agonists with an analgesic action.
AID610905Binding affinity at human CB1 receptor expressed in CHO-K1 cells at 10 uM2011Journal of natural products, Jul-22, Volume: 74, Issue:7
Benzyl derivatives with in vitro binding affinity for human opioid and cannabinoid receptors from the fungus Eurotium repens.
AID1901235Agonist activity at human CB1 receptor expressed in CHO-K1 cells assessed as assessed as induction of beta-arrestin 2 recruitment measured for 90 mins by PathHunter assay2022European journal of medicinal chemistry, Feb-15, Volume: 230Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.
AID1404274Agonist activity at N-terminal HA-tagged human CB1 receptor expressed in HEK293 cells transfected with YFP-Epac-RLuc assessed as decrease in forskolin-stimulated cAMP level by BRET assay relative to control2018European journal of medicinal chemistry, Feb-10, Volume: 145Alkyl indole-based cannabinoid type 2 receptor tools: Exploration of linker and fluorophore attachment.
AID1573479Agonist activity at GFP-fused human CB1 receptor assessed as increase in beta-arrestin-2 recruitment by BRET-based luciferase reporter gene assay relative to control2018Journal of medicinal chemistry, 11-21, Volume: 61, Issue:22
Biased Ligands of G Protein-Coupled Receptors (GPCRs): Structure-Functional Selectivity Relationships (SFSRs) and Therapeutic Potential.
AID274530Selectivity for CD1 mouse CB2 receptor over CB1 receptor2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide.
AID1744381Agonist activity at human CB2 receptor expressed in HEK293 cells assessed as inhibition of forskolin-induced cAMP production incubated for 15 mins by cAMP HTRF assay2021Journal of medicinal chemistry, 01-14, Volume: 64, Issue:1
From a Designer Drug to the Discovery of Selective Cannabinoid Type 2 Receptor Agonists with Favorable Pharmacokinetic Profiles for the Treatment of Systemic Sclerosis.
AID1491457Agonist activity at CB1 receptor (unknown origin) expressed in CHO cells assessed as induction of calcium mobilization by fluo-4 AM dye-based fluorescence assay2017European journal of medicinal chemistry, Sep-08, Volume: 137Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
AID1564091Agonist activity at human CB2 receptor expressed in AtT-20 cells at 1 uM measured every 2 secs for 2 mins by FLIPR assay relative to control2019European journal of medicinal chemistry, Oct-15, Volume: 180Strategies to develop selective CB
AID1847546Agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation by measuring maximum efficacy preincubated for 15 mins followed by forskolin stimulation and measured after 15 mins by 2021European journal of medicinal chemistry, Dec-15, Volume: 226Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID524792Antiplasmodial activity against Plasmodium falciparum D10 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID1399865Agonist activity at recombinant rat Cb1 receptor expressed in HEK293 cells assessed as inhibition of forskolin-stimulated cAMP levels relative to control2018Bioorganic & medicinal chemistry, 10-01, Volume: 26, Issue:18
Oximes short-acting CB1 receptor agonists.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1416642Displacement of [3H]CP55940 from beta-galactosidase reporter fused human CB1 receptor expressed in CHOK1 cell membranes after 1 hr by scintillation spectrometric analysis2017MedChemComm, Aug-01, Volume: 8, Issue:8
Bioisosteric replacement of central 1,2,4-oxadiazole ring of high affinity CB
AID1847545Agonist activity at recombinant human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation preincubated for 15 mins followed by forskolin stimulation and measured after 15 mins by HTRF assay2021European journal of medicinal chemistry, Dec-15, Volume: 226Carbon-silicon switch led to the discovery of novel synthetic cannabinoids with therapeutic effects in a mouse model of multiple sclerosis.
AID1901236Agonist activity at human CB1 receptor expressed in CHO-K1 cells assessed as assessed as induction of beta-arrestin 2 recruitment measured for 90 mins by PathHunter assay relative to control2022European journal of medicinal chemistry, Feb-15, Volume: 230Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists.
AID1350536Agonist activity at N-terminal FLAG-tagged human CB1 receptor transfected in human HTLA cells assessed as induction of beta-arrestin-recruitment after 8 to 14 hrs by bright-glo luminescence based assay2018Journal of medicinal chemistry, 07-12, Volume: 61, Issue:13
Antitumorigenic Properties of Omega-3 Endocannabinoid Epoxides.
AID1346728Human CB2 receptor (Cannabinoid receptors)1996The Journal of biological chemistry, Mar-22, Volume: 271, Issue:12
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.
AID1346701Human CB1 receptor (Cannabinoid receptors)1996The Journal of biological chemistry, Mar-22, Volume: 271, Issue:12
Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A.
AID1346728Human CB2 receptor (Cannabinoid receptors)1996European journal of biochemistry, May-01, Volume: 237, Issue:3
Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression.
AID1346701Human CB1 receptor (Cannabinoid receptors)1991The Biochemical journal, Oct-01, Volume: 279 ( Pt 1)Molecular cloning of a human cannabinoid receptor which is also expressed in testis.
AID1346701Human CB1 receptor (Cannabinoid receptors)1992Molecular pharmacology, Nov, Volume: 42, Issue:5
Cannabinoid agonists stimulate both receptor- and non-receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones.
AID1346701Human CB1 receptor (Cannabinoid receptors)1995The Biochemical journal, Dec-01, Volume: 312 ( Pt 2)Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1.
AID1346728Human CB2 receptor (Cannabinoid receptors)1996Biochimica et biophysica acta, Jun-07, Volume: 1307, Issue:2
Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor.
AID1346701Human CB1 receptor (Cannabinoid receptors)1995The Journal of biological chemistry, Jun-09, Volume: 270, Issue:23
Stimulation of cannabinoid receptor CB1 induces krox-24 expression in human astrocytoma cells.
AID1346728Human CB2 receptor (Cannabinoid receptors)1993Nature, Sep-02, Volume: 365, Issue:6441
Molecular characterization of a peripheral receptor for cannabinoids.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1799559Binding Assay from Article 10.1016/j.chembiol.2011.05.012: \\Mechanisms of Osteoclastogenesis Inhibition by a Novel Class of Biphenyl-Type Cannabinoid CB(2) Receptor Inverse Agonists.\\2011Chemistry & biology, Aug-26, Volume: 18, Issue:8
Mechanisms of osteoclastogenesis inhibition by a novel class of biphenyl-type cannabinoid CB(2) receptor inverse agonists.
AID1802434Radioligand Binding Assay from Article 10.1074/jbc.M113.489153: \\Molecular basis of cannabinoid CB1 receptor coupling to the G protein heterotrimer Gaiu00DFu00BF: identification of key CB1 contacts with the C-terminal helix a5 of Gai.\\2013The Journal of biological chemistry, Nov-08, Volume: 288, Issue:45
Molecular basis of cannabinoid CB1 receptor coupling to the G protein heterotrimer Gαiβγ: identification of key CB1 contacts with the C-terminal helix α5 of Gαi.
AID1802031FABP1 Fluorescent Ligand Displacement Assay from Article 10.1021/acs.biochem.6b00446: \\FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.\\2016Biochemistry, 09-20, Volume: 55, Issue:37
FABP1: A Novel Hepatic Endocannabinoid and Cannabinoid Binding Protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (130)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's13 (10.00)18.2507
2000's28 (21.54)29.6817
2010's70 (53.85)24.3611
2020's19 (14.62)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (3.08%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other126 (96.92%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]